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Manvir Kaur, Ph.D.
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The current pandemic of coronavirus disease (COVID-19) caused by the highly
infectious pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
represents a global public health challenge. The emergence of deadly SARS-CoV-2
variants with mutations on the viral genes has made it more imperative to discover
therapeutics that target the host receptors for COVID-19 treatment. Therefore, our
research has targeted the critical host entry receptor: Angiotensin-converting enzyme-2
(ACE2) for SARS-CoV-2 entry into the human cells.
SARS-CoV-2 is an enveloped RNA beta coronavirus that infects human cells via
interaction with the ACE2 receptor, followed by viral replication and virus dissemination.
Spike protein of SARS-CoV-2 has a receptor-binding domain (RBD), which binds to the
host ACE2 receptor. ACE2 is an essential component of the Renin-Angiotensin System
(RAS) that converts Angiotensin II (Ang II) to Angiotensin 1-7, a potent vasopressor.
Even though ACE2 facilitates viral entry, it provides defense against acute lung injury,

1

2
indicating that the ACE2/Ang 1-7 pathway must be carefully manipulated to reduce
SARS-CoV-2 induced lung injuries.
Herein, we discovered that OJT010 targets the interaction between RBD and
rhACE2 without inhibiting the exopeptidase activity of rhACE2. Our findings reveal that
OJT010 binding to rhACE2 may potentially preserve its physiological function and
prevention exacerbation of the disease. Furthermore, it will potentially prevent non-target
cardiac toxicities observed in other ACE2 modulating drugs. Moreover, we discovered
that OJT010 inhibits the cellular entry and further replication of the SARS-CoV-2 and
B.1.617.2 Delta Variant in three independent assays; Infection Induced Cytopathic Effect
(CPE), Nanoluciferase reporter assay (NLRV), and Pseudotyped Lentiviral assay. In
addition, we have also assessed the molecular interactions of the compounds with the
host and viral receptor using molecular dynamic simulation of the best-fit docking
complex to elucidate the binding sites of OJT010. Next, we have determined the
pharmacokinetics (PK) parameters of OJT010 in healthy rats. We have further advanced
into a hamster of model SARS-CoV-2 infection to evaluate the efficacy of OJT010
against SARS-COV-2 infection in vivo.
Based on our findings, OJT010 represents a promising drug that could be further
evaluated as a lead series in developing chemotherapeutics for COVID-19 treatment.
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CHAPTER 1
INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus,
has quickly escalated into an unexpected and devastating pandemic of coronavirus
disease 2019 (Morens & Fauci, 2020). As of March 12th, 2022, over 450 million cases
have been detected, with more than 6 million deaths recorded worldwide
(@JohnsHopkins, 2022). It has become a public health crisis, which has not only
overwhelmed the health care system but has also affected the global economy (Shang et
al., 2021). Because of the severity of the continuing COVID-19 pandemic, it is
imperative to develop antiviral drugs, vaccines, and antibodies as quickly as possible.

While there has been substantial development in developing therapeutics,
treatment options for COVID-19 remained extremely limited (@US_FDA, 2022a).
Although vaccination is an effective measure, limitation in global access and
uncertainties about the duration of protection represents significant challenges to
overcome. Moreover, with the emergence of SARS-CoV-2 variants it’s now more
evident that simply two doses of vaccines are not enough to contain the spread of SARSCoV-2 (J. L. Bernal et al., 2021; Burki, 2022).
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Despite the fact that the Food and Drug Administration (FDA) has approved
numerous drugs, including antivirals, corticosteroids, monoclonal antibodies and
immune modulators, only one drug; remdesivir is fully authorized to treat COVID-19
(@US_FDA, 2022a).

More recently, two new drugs, Molnupiravir and Paxlovid, were also granted an
emergency use authorization (EUA) for the treatment of COVID-19 infection in adults
and pediatric patients ("Molnupiravir for treatment of COVID-19," 2022; "Paxlovid for
treatment of COVID-19," 2022). However, no therapies have been shown to speed up the
viral clearance and prevent transmission. As a result, SARS-CoV-2 continues to spread
globally, contributing to high morbidity and mortality (@JohnsHopkins, 2022).
Moreover, due to cost and availability, it’s unlikely that these treatments will be available
to low and middle-income countries (Andrew Hill, 2022). Furthermore, there is a
possibility that monotherapy will causes escape mutants over time. Therefore, it is
essential to explore innovative strategies in antiviral drug discovery to contain this
pandemic.

Understanding the structure of SARS-CoV-2 and its interaction with host protein,
may aid in the development of more effective antiviral therapies. SARS-CoV-2 is a
positive-sense single-stranded RNA beta coronavirus that infects human cells via
interaction with the Angiotensin-converting enzyme 2 receptor, followed by viral
replication and virus dissemination (Walls et al., 2020; Q. Wang et al., 2020; Wrapp et
al., 2020; Yan et al., 2020). Structural studies have shown that the receptor-binding

3

domain of spike glycoprotein (S) of the SARS-CoV-2 binds to the host cell receptor that
triggers the fusion between the viral membrane and cellular membrane, resulting in entry
of SARS-CoV-2 into the cell. This interaction has been confirmed as an initial and
critical step in the viral infection (Walls et al., 2020; Q. Wang et al., 2020; Wrapp et al.,
2020; Yan et al., 2020). The binding between the RBD of the SARS-CoV-2 subunit to the
peptidase domain (PD) of ACE2 is emerging as a promising therapeutic target.

The COVID-19 global emergency has raised an urgent need to develop antiviral
drugs, which prompted scientists worldwide to discover novel and potent therapeutics
agents against SARS-CoV-2. However, the traditional screening and lead optimization
approaches are expensive ventures, and highly resources and time-consuming (Wouters
et al., 2020). Therefore, more innovative methods and faster strategies are needed to
facilitate drug discovery. Given the severity of the pandemic, repurposing of clinically
approved drugs to expedite the traditional process of drug discovery is an emerging
strategy, with low cost, shorter development period, and minimum risk of failure
(Pushpakom et al., 2019).

Drug repurposing is a highly promising approach to accelerate the development
process by identifying novel therapeutic opportunities for FDA-approved drugs that have
already been shown to be safe and effective in humans for other indications (Pushpakom
et al., 2019). The rationale behind drug repurposing is that the same molecular pathways
may be involved in different diseases, or a drug molecule may have pharmacological
activity on other targets, suggesting a new possible indication of use (Pushpakom et al.,
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2019). For example, remdesivir was initially developed against the Ebola virus and is
now being repurposed for COVID-19 (Consortium et al., 2021). In fact, multiple
repurposed drugs are being tested in clinical trials for COVID-19 treatment (Saul &
Einav, 2020).

To discover new antivirals among repurposed drugs for COVID-19, this study
discusses the serendipity of OJT010 as a novel antiviral that showed superior
pharmacological efficacy at the molecular and cellular level against SARS-CoV-2 in the
micromolar range. OJT010 is a mucolytic agent used to treat respiratory diseases and is
well tolerated and safe (Nobata et al., 2006; Olivieri et al., 1987). It has been shown to
improve the clinical course of respiratory diseases and reduce the incidence of
postoperative pulmonary complications (Fegiz, 1991). In this study, we explored the
effects of OJT010 on disrupting the interaction between recombinant human ACE2
(rhACE2) and the RBD of the S protein of SARS-CoV-2. We also determined the impact
of OJT010 on viral replication through three individual assays: Nanoluc Reporter Virus
and SARS-CoV-2 infection-induced cytopathic effect using wild type and delta variants
of SARS-CoV-2 and Pseudotyped lentiviral assay.

Furthermore, we have assessed the effect of combination therapy of OJT010 with
remdesivir against SARS-CoV-2. Additionally, we have also determined the cytotoxicity
of OJT010 in comparison to other clinically approved drugs. Next, we have also
investigated the impact of OJT010 on the exopeptidase activity of rhACE2. We have
determined the pharmacokinetic parameters of OJT010 in healthy rats. Herein, we found
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that OJT010 effectively modulated the interaction between rhACE2 and RBD of spike
protein in the micromolar range. We also discovered that OJT010 inhibited replication of
wild and delta variants of SARS-CoV-2 in NLRV, CPE, and Pseudotyped virus assay in
the micromolar range. Furthermore, we are reporting for the first time that OJT010
doesn’t inhibit the exopeptidase activity of rhACE2. Altogether, the potent efficacy,
excellent safety, and pharmacologic profile of OJT010, along with its affordability and
availability, makes it a promising candidate for drug repurposing as possible prophylactic
and treatment options against SARS-CoV-2 infection.

CHAPTER 2
LITERATURE REVIEW
2.1 Severe Acute Respiratory Syndrome Coronavirus 2

In December 2019, a newly recognized illness spread through the Huanan
Seafood Wholesale Market in Wuhan, Chain, and worldwide. It started with an upper
respiratory tract infection and quickly escalated into pneumonia and eventually
respiratory failure (Z. N et al., 2020). The etiological agent was a new coronavirus called
SARS-CoV-2 that caused a disease named COVID-19 (Lu et al., 2020). The disease
quickly expanded globally, and by March 11, 2020, it was declared a pandemic. As of
February 21, 2022, COVID 19 has affected 188 countries worldwide, with over 500
million confirmed cases and a death toll of over 5 million (@JohnsHopkins, 2022).

2.1.1 Pathophysiological, and Epidemiological Features

Patients with SARS-CoV-2 infections have diverse clinical outcomes with mild to
moderate symptoms such as fever, cough, fatigue, headache, diarrhea, and shortness of

6

7
breath: subset progresses to severe acute respiratory distress syndrome (ARDS) with
massive alveolar damage and impaired lung function (Guan et al., 2020; Mason, 2020;
Yang et al., 2020). Although the respiratory tract is the gateway for SARS-CoV-2
infection, reports of extrapulmonary manifestations involving cardiovascular, renal,
gastrointestinal, hematologic, and neurologic systems are increasing, suggestive of a
vascular infection rather than a purely respiratory disease (Ellul et al., 2020; Gross et al.,
2020; Gupta et al., 2020).

Around 80% of patients infected with SARS-CoV-2 are asymptomatic or have
mild to moderate illness primarily affecting the upper respiratory tract. While the
remaining 20% will develop severe symptomatic infection necessitating hospitalization,
5% will require ventilation support in the Intensive Care Unit (ICU) (Wu & McGoogan,
2020). Individuals, particularly those over the age of 65 and those who have comorbid
conditions such as respiratory disorders, diabetes, cardiovascular and cerebrovascular
disease are at an increased risk of death (C. N et al., 2020). More importantly, male
patients are more susceptible to this disease and are significantly impacted by it.
Men, especially older accounted for nearly 70% of those infected with SARS-CoV-2
(Yang et al., 2020).

Clinical stages of infection are associated with pathogenic events that occur once
the virus infects the lungs. Clinical symptoms and pathogenic events associated with any
infectious disease, particularly COVID-19, should be viewed through the damageresponse lens. Various elements and factors can tip the balance in favor of the host or
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pathogen (Pirofski & Casadevall, 2018). Thus, the virus may occasionally act as an
initiator rather than a perpetrator. The host's forces are released due to the virus's
presence that causes uncontrolled inflammatory immune responses, which drives
cytokines storm and causes tissue and organ damage (D. P et al., 2020; Z et al., 2020).

2..1.2 Origin of SARS-CoV-2

In the past two decades before COVID 19, two other significant coronaviruses;
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East
Respiratory Syndrome Coronavirus (MERS-CoV) have been identified and to date, seven
coronaviruses have been discovered (Lu et al., 2020; Zhang & Holmes, 2020).
Coronaviruses are members of the “Nidovirales” family of viruses. The coronavirus
family comprises four subgenera (alpha, beta, gamma, and delta coronaviruses). Human
coronavirus (HCoVs) falls under the two of these genera (alpha coronaviruses and beta
coronaviruses). HCoV-229E and HCoV-NL63 are alpha coronaviruses that infect
humans, whereas HCoV-HKU1, HCV-OC43, MERS-CoV, SARS-CoV, and SARSCoV-2 are beta coronaviruses that infect humans (Chan et al., 2015; Lefkowitz et al.,
2018).

SARS-CoV-2 is a positive-sense single-stranded RNA beta coronavirus that
infects human cells via interaction with the ACE2 receptor, followed by viral replication
and virus dissemination (Wrapp et al., 2020; Yan et al., 2020; Yan et al., 2022). The
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sudden emergence and rampant spread of SARS-CoV-2 have raised several questions on
its genomic evolution and genetic recombination.

SARS-CoV-2 shares 79% of structural identity with SARS-COV and 50% with
MERS-CoV (Kim et al., 2020). The genome of SARS-CoV-2 is closely related to the bat
coronavirus RaTG13/2013 (RaTG13), sharing 96 % sequence identity, implying that both
viruses share a common ancestor (Kim et al., 2021). Nevertheless, the SARS-CoV-2
genome also shows evidence of genetic recombination with at least two different viruses
from different clusters, inferring that this virus might not be directly transferred from bats
to humans or could be a result of convergent evolution. Moreover, the uncanny
resemblance in a sequence of S1 protein of SARS-CoV-2 among human isolates, which
is uncommon for RNA viruses, indicates a recent recombination event that happened in
the intermediate host before jumping to the human (Zhang & Holmes, 2020). Concurrent
evidence has found high sequence similarities between RBD of pangolin CoV and SARSCoV-2 and proposed them as a potential reservoir species, suggesting the possibility of
pangolins serving as an intermediate host before jumping into the human (Sun et al.,
2020).
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2.1.3 Genome of SARS-CoV-2

SARS-CoV-2 is an enveloped positive-sense single-stranded RNA virus with a
genome of around 30 kb (Lu et al., 2020). SARS-CoV-2 genome encodes five major
open reading frames (ORFs) (Michel et al., 2020). The two large ORF1a and ORF1b
occupy the two-thirds length of the viral RNA. Upon-cell entry, the genomic RNA is
translated to make proteins from two ORFs; ORF1a and ORF1b. The ORF1a is translated
to produce polypetide1a, which is then cleaved into 11 nonstructural proteins (nsps). The
ORF1b yields a large polypeptide translated into 15nsps (Kim et al., 2020). The viral
proteases nsp3 and nsp5, which have a papain-like protease (PLpro) domain and a 3Clike protease (3CLpro) domain, are responsible for the proteolytic cleavage (Kim et al.,
2020). The viral genome serves as a template for replication and transcription, mediated
by the RNA-dependent RNA polymerase (RdRP) activity of the nsp12 protein. Negativesense RNA intermediates are produced to serve as templates for creating positive-sense
genomic and subgenomic RNAs (sgRNAs). The structural proteins bundle the gRNA
to assemble progeny virions. The remaining part of the genome is translated into
structural proteins Spike (S), Envelope (E), Nucleocapsid (N), and Membrane (M)
proteins, and several accessory proteins whose functions are yet to be discovered.
According to the present annotation, SARS-CoV-2 has at least six accessory proteins (3a,
6, 7a, 7b, 8, and 10) (Kim et al., 2021).
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Figure 1: Genome Organization of SARS-CoV-2

Reprinted from "Genome Organization of SARS-CoV", by BioRender, August 2020, retrieved
from https://app.biorender.com/biorendertemplates/t5f99ec8322469900a3546483-genomeorganization-of-sars-cov Copyright 2022 by BioRender.
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2.1.4 Cellular Entry/Life Cycle of SARS-CoV-2

SARS-CoV-2 enters the cell by two main pathways:

1. Endocytic pathway
2. Cell fusion pathway

Structural studies have shown that the spike glycoprotein of the SARS-CoV-2
binds to the host cell receptor and fuses the viral membrane with a cellular membrane
(Wrapp et al., 2020). The first pathway involves receptor-mediated endocytosis, whereas
the second pathway involves plasma membrane fusion following S protein attachment
with ACE2 receptor (Jackson et al., 2022). The trimeric S protein of SARS-CoV-2 is
cleaved into S1 and S2 during their biosynthesis in virus-producing cells by furin, a host
protease (Xia et al., 2020). The S protein contains non-covalently associated S1 and S2
subunits in mature virions. S1 includes the receptor-binding domain, which binds to the
peptidase domain (PD) of its cognate receptor angiotensin-converting enzyme 2, whereas
S2 is responsible for membrane fusion.

The binding of S1 to the host receptor ACE2 exposes another cleavage site on S2
(Walls et al., 2020; Q. Wang et al., 2020; Wrapp et al., 2020; Yan et al., 2020). The S2
subunit is cleaved by the host transmembrane protease, serine 2 (TMPRSS2), at the cell
surface or by cathepsin L in the endosomes, following the endocytic pathway. A twostep sequential protease cleavage by host cell proteases at S1/S2 and the S2 sites is
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crucial for viral entry into the host cells (Hoffmann et al., 2020; Ou et al., 2020). This
interaction has been confirmed as an initial and critical step in the viral infection (Walls
et al., 2020; Q. Wang et al., 2020; Wrapp et al., 2020; Yan et al., 2020). The binding
between the RBD of the SARS-CoV-2 subunit to the peptidase domain of ACE2 is
emerging as a promising therapeutic target.

Following-cell entry, the viral RNA is released into the host cytosol. The SARSCoV-2 gRNA serves as mRNA to translate the two large polyproteins, which are further
cleaved by viral proteases, into nonstructural proteins (Lu et al., 2020; Meyer et al.,
2021). The SARS-CoV-2 genome serves as a template for replication and transcription,
mediated by the RNA-dependent RNA polymerase (RdRP) activity of the nsp12 protein
(Gao et al., 2020). The four structural proteins (S, M, E, and N) required for the virion
assembly are translated by host ribosomes. Then mature virions are released from the cell
by lysosomal trafficking from the infected cell (Malone et al., 2022).
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Figure 2: The Life Cycle of SARS-CoV-2

Reprinted from "Coronavirus Replication Cycle", by BioRender, July 2020, retrieved from
https://app.biorender.com/biorender-templates/t-5e56d97d1b689000850f8f93-coronavirusreplication-cycle.
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2.2 FDA Approved Therapeutics for COVID-19 Treatment

The COVID-19 pandemic has sparked a tremendous search and investment
worldwide to identify effective treatments at all stages of the disease. On a global scale,
numerous attempts have been made to determine the appropriate therapeutic drugs to
treat COVID-19 (Bugin & Woodcock, 2021). In the past two years, FDA has approved
three vaccines and a single fully authorized drug for the treatment of COVID-19
(@US_FDA, 2022a). However, a few more drugs are approved under EUA against
SARS-CoV-2 (@US_FDA, 2022a). This section will briefly discuss the approved
vaccines and treatments measures for COVID 19.

2.2.1 Remdesivir

Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase inhibitor, is the
only FDA-approved drug for the treatment of COVID-19. A nucleotide analog prodrug is
metabolized in cells to yield pharmacologically active remdesivir triphosphate (RDV-TP)
that inhibits the viral RdRP (Agostini et al., 2018; Grein et al., 2020; Teoh et al., 2020).
It has a broad-spectrum antiviral activity against several viruses, including SARS-CoV,
MERS-CoV, and Ebola (Gordon, Tchesnokov, Feng, et al., 2020; J. Wang et al., 2021).
Biochemical studies showed that the RdRp could use RDV-TP as a substrate and
incorporate RDV-TP into the growing RNA product. Unlike with many other classic
chain terminators, inhibition is not seen immediately after incorporation of RDV-TP, but
instead, it’s delayed by three more nucleotides before it induces an irreversible chain
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termination (Gordon, Tchesnokov, Woolner, et al., 2020; Jordan et al., 2018; Siegel et al.,
2017; J. Wang et al., 2021). Although the clinical efficacy and safety of remdesivir for
COVID-19 treatment have been evaluated in various clinical trials, early studies provided
conflicting evidence on its effectiveness among hospitalized COVID-19 patients (M et
al., 2021; McCreary et al., 2022). Because the available evidence is insufficient to
recommend either for or against routine remdesivir treatment for all hospitalized patients
with moderate COVID-19, it is left on clinicians to determine the appropriate use of
remdesivir in COVID-19 patients (Consortium et al., 2021; G et al., 2021; Grein et al.,
2020; Paladugu & Donato, 2020).

17

Figure 3: Mechanism of SARS-CoV-2 Inhibition by Remdesivir

Reprinted from "Remdesivir: Potential Repurposed Drug Candidate for COVID-19 (Portrait)", by
BioRender, April 2020, retrieved from https://app.biorender.com/biorendertemplates/figures/all/t-5ea056e2183b5d00b114231f-remdesivir-potential-repurposed-drugcandidate-for-COVID-19- Copyright 2022 by BioRender.
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2.2.2 Monoclonal Antibodies

Monoclonal antibodies are lab-made molecules engineered to mimic the immune
system to counteract harmful pathogens such as viruses like SARS-CoV-2 (J et al., 2022).
FDA has approved four monoclonal antibodies under EUA for the treatment of COVID19 (@US_FDA, 2020).

a) Bamlanivimab plus etesevimab,
b) Casirivimab plus imdevimab (REGEN-COV)
c) Sotrovimab
d) Tixagevimab plus cilgavimab
e) Bebtelovimab

The anti-SARS-CoV-2 antibodies target different epitopes of spike protein: S1RBD, S1-NTD, or the S2 region. They prevent/block the interaction of RBD with the
ACE2 and interfere with the S2-mediated membrane fusion process, preventing viral
particles from entering the host cell and thus reducing viral infections (Group et al., 2022;
Group et al., 2021).

SARS-CoV-2, like other infectious organisms, can mutate over time, making
specific treatments ineffective against variants such as the omicron (VanBlargan et al.,
2021; P. Wang et al., 2021). Therefore, recently FDA revised its recommendation and
advised to limit the use of bamlanivimab plus etesevimab and Casirivimab plus
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imdevimab (REGEN-COV) because of the preclinical evidence demonstrating lack of
efficacy and reduced neutralizing activity of these antibodies against the recently
emerged omicron variants of the SARS-CoV-2 (@US_FDA, 2022b; Group, 2022;
Weinreich et al., 2021).

2.2.3 Immune Modulators

According to our current understanding of COVID-19, the immune system plays a
significant role in defining the disease's severity. SARS-CoV-2 interacts closely with an
individual's immune system, resulting in many clinical manifestations. Most SARS-CoV2 infected people are asymptomatic, which shows that this virus can elicit a robust,
resistant response (Group et al., 2021).

The immune system can become hyperactive in COVID-19 infection, leading to
disease progression (D. P et al., 2020). To prevent the disease progressing to its most
severe manifestations, the immune system must be addressed and controlled in addition
to the virus-targeting treatment approaches. Immune modulators can aid in the reduction
of hyper inflammation (Feuillet et al., 2021; Paces et al., 2020).

FDA has issued an EUA for Corticosteroids; dexamethasone, Interleukin-6
inhibitors: tocilizumab (or sarilumab), and Janus kinase (JAK) inhibitors: baricitinib (or
tofacitinib) (@US_FDA, 2022a). Tocilizumab is a monoclonal antibody that decreases
inflammation by blocking the interleukin-6 receptor in the COVID patient’s (Group,
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2021; Gupta et al., 2021). However, due to conflicting evidence on their approved dose
and pharmacokinetics of these drugs, they are only recommended in patients with severe
or critical COVID-19.

2.2.4 Paxlovid (Ritonavir-Boosted Nirmatrelvir)

Nirmatrelvir is an orally bioavailable, reversible inhibitor of the main protease
(3CLPro) of SARS CoV-2. The 3CLPro viral protease plays a critical role in viral
replication by cleaving the two viral polyproteins (Owen et al., 2021). Nirmatrelvir is a
potent inhibitor of all alpha and beta coronavirus known to infect humans (Pillaiyar et al.,
2016). Nirmatrelvir is co-administered with ritonavir (marketed under the brand name
Paxlovid), a potent cytochrome P450 3A4 inhibitor, and enhances the pharmacokinetic of
nirmatrelvir. It is necessary to take ritonavir to raise nirmatrelvir concentrations to
desired therapeutic ranges (Hammond et al., 2022). However, nirmatrelvir boosted with
ritonavir can cause significant drug-induced toxicity (Owen et al., 2021; Pillaiyar et al.,
2016). In the EPIC-HR trial, ritonavir-boosted nirmatrelvir significantly reduced the risk
of hospitalization or death in non-hospitalized adults with laboratory-confirmed SARSCoV-2 infection by 89 percent when compared to the placebo (Hammond et al.,
2022). Based on the recent preprint Paxlovid potentially inhibited viral variants of
SARS-CoV-2 in two separate in vitro assays (Vangeel et al., 2022).
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2.2.5 Molnupiravir

Molnupiravir is the oral prodrug of the nucleoside analog beta-D-N4hydroxycytidine (Jayk Bernal et al., 2022; "Molnupiravir for treatment of COVID-19,"
2022). In phase II clinical trials, administration of molnupiravir caused a 30 % reduction
in hospitalization or death compared to the placebo group (A. J. Bernal et al., 2021). It
has a broad range of antiviral activity against a wide range of RNA viruses (Costantini et
al., 2012; Painter et al., 2019; Reynard et al., 2015; Sheahan et al., 2020; Yoon et al.,
2018). Molnupiravir was originally discovered as an inhibitor of the influenza virus, later
repurposed for SARS-CoV-2 (Reynard et al., 2015). Molnupiravir has a comparable
potency to remdesivir against SARS-CoV-2 in vitro (Sheahan et al., 2020; Tao et al.,
2021).

The mechanism of action includes lethal mutagenesis; RdRp uses molnupiravir as
a substrate during replication instead of cytidine triphosphate or uridine triphosphate
(Sheahan et al., 2020). Uptake of molnupiravir by viral RNA-dependent RNApolymerases introduces mutations that cause an error catastrophe during the viral
replication (Kabinger et al., 2021; Zhou et al., 2021). However, due to lack of safety
data, the long-term harms of molnupiravir remains a matter of concern.

As a mutagenic ribonucleoside antiviral agent, the possibility exists that
molnupiravir will be metabolized by the human cells and might be incorporated into the
host DNA, leading to mutations (Kabinger et al., 2021; Zhou et al., 2021). Moreover, it’s
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been proposed that random mutagenesis occurring in the viral genome due to the
molnupiravir mechanism of action over time might generate new variants of SARS-CoV2 due to increased diversity in viral sequence (CJ et al., 2021). In the absence of research
evidence regarding safety and efficacy, molnupiravir might only be favoured to treat
high-risk groups.

2.2.6 Vaccines

To date, FDA has approved three vaccines as preventive measures against covid 19

a) Pfizer-BioNTech COVID-19 Vaccine
b) Moderna COVID-19 vaccine
c) The Janssen COVID-19

The mRNA vaccines are nucleoside-modified RNA that encodes the full-length
spike protein of SARS-CoV-2, modified by two proline mutations (Walsh et al., 2020).
The spike protein is locked in the prefusion conformation that mimics the intact virus and
elicits an immune response to provide antigenicity (Walsh et al., 2020). Both Pfizer and
Moderna vaccines are 95% and 94.1% efficacious at preventing COVID-19 illness and
severe disease. At the same time, the Janssen COVID-19 vaccine is 77-85% efficacious
at preventing strong to critical COVID-19 infection (Baden et al., 2021; Polack et al.,
2020; Sadoff et al., 2021).
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Figure 4: NIH Treatment Guidelines for COVID-19

US State and Health Services. NIH guidelines for the treatment of COVID-19. Retrieved
from(https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/USG-COVID19-TxPlaybook.pdf)
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2.3 Drug Discovery and Development for the Treatment of COVID-19

Why need still need new therapeutics for COVID-19?

Several vaccines and drugs have been developed to prevent and treat COVID-19.
Some have been proven to be efficacious and safe to a certain level. Despite this, relying
solely on the available treatments would be unwise for several reasons. The range of
challenges that need to be addressed are limited availability, high cost, need for
parenteral administration and monitoring in a health care setting. Moreover, the SARSCoV-2 continues to mutate. The emerging viral variants such as highly infectious Delta
and Omicron have become more immune to the currently approved vaccine, monoclonal
antibodies, and drugs. Therefore, there is a need for safe and effective oral treatments for
COVID-19 that can be taken in the earliest stages of infection to prevent its progression
to more severe disease, hospitalization, and death. Such treatment would help mitigate
the spread of the infection, hospitalization, and mortality. Thus, reducing the burden on
the healthcare system and global economy.

A better understanding of viral and host pathways that are crucial for infection
and viral survival will help in the development of potent and targeted antiviral. In the
following section, I will discuss the critical viral and host proteins and enzymes involved
viral life cycle.
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2.3.1 Pharmacological Targets for Drug Discovery in COVID-19
Pathogenesis Pathway

Severe acute respiratory syndrome coronavirus 2, a novel and highly pathogenic
virus, continues to pose a public health threat worldwide. To date, new SARS-CoV-2
variants with mutations in the viral genes are quickly spreading (VP, AB, et al., 2022). To
contain the pandemic, efficient therapeutic measures are needed now more than ever. In
order to develop effective therapeutic interventions against SARS-CoV-2 infection, it is
required to inhibit critical viral entry and post-entry processes by targeting viral enzymes
or host receptors.(VP, C, et al., 2022). I will briefly discuss important proteins of the
virus that could be targeted to develop countermeasures against SARS-CoV-2.

2.3.1.1 Viral Targets

The structural proteins, (S, E, M, N) proteases and replication enzymes play an
essential function in the viral life cycle and are an attractive pharmacological target for
drug discovery.

2.3.1.2 Spike Protein

The S protein is a type 1 membrane protein responsible for receptor recognition,
attachment, and membrane fusion. In its functional form the monomeric S protein
assembles as a homotrimer. The S1 subunit is organized into four subdomains:
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a) N terminal domain
b) C terminal domain is also known as RBD domain
c) SD1 and SD2 subdomains

The S2 subunit contains an N-terminal fusion peptide, two heptad repeats, a
transmembrane domain, and a cytoplasmic tail. The S protein exists in various
configurations and undergoes substantial structural rearrangement between the prefusion
and post-fusion stages. In the prefusion location, the binding of ACE2 destabilizes the S1
subunit, resulting in the shedding of S1 and the S2 subunit transitioning to a stable postfusion configuration. The receptor-binding domain of S1 undergoes hinge-like
conformational motions to engage a host cell receptor, temporarily hiding or exposing the
determinants of receptor binding. The S protein is a target for antibody-mediated
neutralization because of its essential function, and analysis of the prefusion S structure
would provide atomic-level information to assist the vaccine design and development
(Jackson et al., 2022; Wrapp et al., 2020).

The binding between the RBD of the SARS-CoV-2 subunit to the peptidase
domain of ACE2 is emerging as a promising therapeutic target. In vitro studies have
demonstrated that recombinant soluble ACE2 (Monteil et al., 2020) and ACE2-Fc (Lei et
al., 2020) have potential applications in the prevention and treatment of SARS-CoV-2
infection. Moreover, small molecules that can interact with the majority of RBD residues
or ACE2 residues could potentially disintegrate the binding and prevent SARS-CoV-2
entry into the cells (Gil et al., 2020).
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Although the other three structure proteins: E, M, N, have gained attention and are
indispensable for viral functioning, structural information on these proteins is limited.
Nucleocapsid protein plays a multifaceted role in viral infection and is responsible for
packing viral RNA into ribonucleoprotein complexes. The M protein is embedded in the
viral membrane and is responsible for assembling the new viral particles with the host
cell. Finally, the envelope protein is involved in the recruitment of the endoplasmic
reticulum through its interaction with the M protein (Mariano et al., 2020).
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Figure 5: Structure of SARS-CoV-2 Spike Protein
Reprinted from "An In-depth Look into the Structure of the SARS-CoV2 Spike Glycoprotein", by
BioRender, August 2020, retrieved from https://app.biorender.com/biorendertemplates/figures/5e99f5395fd61e0028682c01/t-5f1754e62baea000aee86904-an-in-depth-lookinto-the-structure-of-the-sars-cov2-spike-g Copyright 2022 by BioRender.
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2.3.1.3 Nonstructural Proteins

The role of most nsps has been reported; however, the function of nsps is still to
be discovered (Lu et al., 2020). Although any nsp could be used as a druggable target, its
essentiality in the viral life cycle and the availability of structural studies increase the
chances of success. Based on this criteria, two major proteases (3C-like and papain-like
protease), and RNA-dependent RNA polymerase (RdRP), are studied extensively to
discover therapeutic for COVID19.

2.3.1.4 SARS-CoV-2 Proteases

3C-like protease (3CLPro) and papain-like protease (PLpro) cleave two large
polyproteins, pp1a and pp1ab, and generate mature nsps. Because of their essentiality in
processing the polyproteins, both proteases are crucial for viral replication and are
attractive drug targets among coronaviruses. Currently, two inhibitors of 3CLpro:
lopinavir and ritonavir, are approved for the COVID-19 treatment (Hilgenfeld, 2014; L.
Zhang et al., 2020).

2.3.1.5 RNA-dependent RNA Polymerase

RdRp is a critical enzyme in the life cycle of coronaviruses and other RNA
viruses. This enzyme is structurally and functionally conserved across viruses with RNA
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genomes from various families. RdRp is a central component involved in the replication
and transcription of the RNA genome (Gao et al., 2020). The lack of a human analog for
this enzyme and its importance in the virus's life cycle makes this enzyme a critical
therapeutic target for antiviral development. The only approved drug for COVID-19,
remedisivir, is an RdRp inhibitor (@US_FDA, 2022a).
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2.3.2 Host Targets

Although targeting viral proteins is a good strategy, emerging viral variants pose a
risk for the emergence of escape mutants against antivirals targeting viral proteins and
enzymes. Therefore, our research has focused on blocking the first step of viral fusion of
SARS-CoV-2 spike protein receptor-binding domain (RBD) with host receptor;
Angiotensin-converting enzyme 2 (ACE2) and thereby prevent the cellular entry of
SARS-CoV-2 into the human cells.

2.3.2.1 Structure of ACE2

ACE2 is an integral type 1 membrane-bound zinc metalloprotease, which
functions exclusively as a carboxypeptidase. This metalloprotease is consisted of 805
amino acids, with a 17 amino acid signal sequence at the N terminal and a putative Cterminal membrane anchor (Towler et al., 2004). Although ACE2 exists as a membrane
protein anchored to the plasma membrane, it can also be found in the plasma or other
body fluids as a soluble, truncated enzyme lacking transmembrane and cytosolic domain
that can cleave the C-terminal residue from angiotensin I and II (Tipnis et al., 2000).

The extracellular region of the ACE2 is composed of two domains: the N-terminal
zinc metallopeptidase domain and a C-terminal domain. The metallopeptidase domain of
ACE2 is subdivided into two subdomains (I & II). These two subdomains together form a
deeply recessed proteolytic active site of the enzyme. The zinc-binding site is situated
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near the bottom of the active site. ACE2 contains a single HEXXH + E zinc-binding
consensus sequence. The zinc ion is coordinated by His374, His 378, Glu 402, and one
water molecule. A chloride ion is bound in the subdomain II coordinated by Arg169,
Trp477, and Lys481 (Towler et al., 2004).

Two forms of mammalian ACE have been identified: somatic ACE containing
two catalytic domains and germinal ACE with a single domain. The catalytic domain of
ACE2 shares 42 % of structural resemblance to each of the catalytic domains of ACE.
ACE2 also shares a 33% similarity to the somatic angiotensin-converting enzyme, a
peptidyl dipeptidase, in the regions surrounding the catalytic domain (Donoghue et al.,
2000; Tipnis et al., 2000; Towler et al., 2004).

2.3.2.2 Substrate Specificity of ACE2

ACE2 is a member of the M2 zinc metalloproteinase family along with somatic
and testicular forms of ACE. ACE2 has a different substrate and inhibitor specificity
from ACE, and hence its physiological function differs from ACE. Moreover, ACE
inhibitors (lisinopril, captopril, and enalaprilat) cannot inhibit the activity of ACE2
(Tipnis et al., 2000). The rationale behind this could be that specific ACE inhibitors are
designed to compete with peptides that are cleaved to release C-terminal dipeptides. In
ACE2, the binding pocket (S2’) is smaller. It can only accommodate one amino acid
instead of a second terminal peptide bond compared with that of testicular ACE (Tipnis et
al., 2000). Therefore, the positioning of inhibitors in the active site of ACE2 may not be
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in the correct conformation to affect the cleavage of single amino acid from the C
terminus of the substrate (Towler et al., 2004). However, EDTA, a metal chelating agent,
completely inhibited the catalytic activity of ACE2 at 10mM (Tipnis et al., 2000).

Unlike ACE, ACE2 has only a single catalytic domain compared to two N & Cterminal domains of somatic ACE. Furthermore, ACE2 specifically acts as
carboxypeptidase rather than dipeptidyl peptidase (Tipnis et al., 2000). ACE2 can cleave
a single hydrophobic or basic residue from the C-terminal of peptides. It cleaves basic
arginine residues from angiotensin I and II (Ang). Bradykinin, which has c-terminal
arginyl residue, is not hydrolyzed by ACE2. The amino acid residue present generally
determines the peptidase cleavage site within four to five positions of the sessile bond.
Proline and leucine are preferred at the P1’ position for substrate hydrolysis (Tipnis et al.,
2000).

2.3.2.3 Expression of ACE2

The expression of ACE2 is highly tissue specific. It is mainly expressed in the
heart, gastrointestinal system, kidney, and testis of the human tissue (Donoghue et al.,
2000). Immunohistochemical analysis shows that ACE2 is localized in the endothelium
of most intramyocardial vessels, including capillaries, veins, coronary arteries. In kidney
cells, the expression of ACE2 was also present throughout the endothelium and in smooth
muscle cells. In the gastrointestinal system, ACE2 is primarily expressed in ileum,
duodenum, jejunum, caecum, and colon (Harmer et al., 2002).
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2.3.2.4 Physiological Role of ACE2

ACE2 has distinct physiologic functions apart from acting as a receptor for
SARS-CoV-2. It plays a vital role in regulating the renin-angiotensin system (RAS) to
maintain blood pressure homeostasis, as well as fluid and electrolyte balance (Boehm &
Nabel, 2002; Corvol et al., 1995; Crackower et al., 2002; Donoghue et al., 2000; Skeggs
et al., 1980; Tipnis et al., 2000). Angiotensin-converting enzyme (ACE) and ACE2 are
homologs but play different RAS roles; ACE generates Angiotensin II (Ang II), whereas
ACE2 inactivates AngII by cleaving the C-terminal residues from it, generating Ang 1-7,
a negative regulator of the RAS system (Boehm & Nabel, 2002; Corvol et al., 1995;
Crackower et al., 2002; Donoghue et al., 2000).

Consequently, ACE2 has a beneficial role in many diseases such as lung injury,
hypertension, cardiovascular diseases, and diabetes (Tikellis & Thomas, 2012). ACE2
cleaves the C-terminal Leu to Ang I to generate Ang 1-9. Similarly, it hydrolyzes the Cterminal residues from three other vasoactive peptides: neurotensin, kinetensin, des-Arg
bradykinin, Ang I, Ang II, and dynorphin A(1-3) and the apelin peptides (Tipnis et al.,
2000).

In SARS-CoV-2 infection, binding of spike protein to its receptor ACE2 causes
downregulation of its expression resulting in increased levels of Ang II, strongly
associated with viral load and lung injury (Liu et al., 2020). Similarly, in the influenza A
(H7N9) virus, elevated levels of Ang II are linked to disease progression and severity and
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may predict patient mortality (Huang et al., 2014). The renin-angiotensin pathway has
been shown to play a critical role in acute pulmonary injury, and ACE2 has a protective
role in the acute pulmonary failure (Kuba et al., 2005). Previous studies have shown the
protective function of ACE2 against lung injury in a mouse model. Interestingly, only
catalytically active recombinant human ACE2 could rescue the lung function, suggesting
a possible therapy to treat acute lung injury (Y et al., 2005). In 2 phase II clinical trials,
the administration of ACE2 decreased Ang II and increased Ang 1–7 levels. However,
the administration of ACE2 did not show any improvement in physiological or clinical
measures of ARDS (Khan et al., 2017). Therefore, potential inhibitors that could
increase ACE2 exopeptidase activity and block RBD and ACE2 interaction represent an
exciting therapeutic option against SARS-CoV-2 infection.

Although ACE2 facilitates viral entry, it provides defense against acute lung
damage, indicating that the ACE2/Ang 1-7 pathway can be carefully manipulated to
reduce SARS-CoV-2 induce lung injuries (Imai et al., 2005; Kuba et al., 2005). It is
already known that the enzymatic site of ACE2 is different from the binding site of RBD,
and potent ACE2 inhibitor MLN-4760 has no effect on the interaction of RBD with
ACE2 (B et al., 2021). Thus, a drug that can target the critical interaction between SARSCoV-2 S glycoprotein and human ACE2, without inactivation of this enzyme and
blocking its crucial beneficial function, represents an exciting therapeutic possibility to
combat SARS-CoV-2 infection.
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Figure 6: SARS-CoV-2 Targeting ACE2 Receptor and Entry in Infected Cell

Reprinted from "SARS-CoV-2 Targeting of ACE2 Receptor and Entry in Infected Cell", by
BioRender, August 2020, retrieved from https://app.biorender.com/biorendertemplates/figures/5e99f5395fd61e0028682c01/t-5f9ae195d8c66d00a335fc7f-sars-cov-2targeting-of-ace2-receptor-and-entry-in-infected- Copyright 2022 by BioRender.
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2.3.3 Host Proteases

Three host proteases play a crucial role in the viral life cycle. Proteolytic cleavage
of S at S1/S2 and the S2′ site protein by host proteases activates the SARS-CoV-2 and
increases its infectivity. Cleavage of the S protein can occur at the plasma membrane
(Furin and TMPRSS2) or in the endosomes before membrane fusion (Cathepsin B/L)
(Hoffmann et al., 2020; Xia et al., 2020). TMPRSS2 is a type II membrane serine
protease essential for many physiological and pathological processes. It is widely
expressed in several organs and tissues, including the prostate, respiratory tract,
gastrointestinal tract, kidney, and pancreas (Wettstein et al., 2022). It activates SARSCoV-2 by proteolytic cleavage at the S2 site, which triggers plasma membrane fusion and
release of viral RNA into the cytoplasm (Hoffmann et al., 2020). Furin-mediated
cleavage at S1/S2 is required for subsequent activation by TMPRSS2. In TMPRSS2
negative cells, the S1/S2 site cleavage is mediated by endosomal protease cathepsin B/L.
Inhibition of cathepsin activity by chloroquine and hydroxychloroquine was unsuccessful
for the treatment of COVID-19, possibly because of the presence of other proteases such
as furin and TMPRSS2 (Hoffmann et al., 2020).

Even though TMPRSS2 mediate S protein cleavage leads to increased uptake and
processing of SARS-CoV-2, cellular entry is partially blocked by a clinically proven
TMPRSS2 inhibitor camostat (Hoffmann et al., 2020). Therefore, inhibitors of furin and
TMPRSS2 might be an option for potential therapeutics for COVID-19. However, unlike
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TMPRSS2, furin is essential for normal development; thus, prolonged inhibition of this
enzyme might be associated with unwanted adverse effects (Xia et al., 2020).

2.3.4 Auxiliary SARS-CoV-2 Receptors

Several host receptors function as co-receptors or cofactors and aid in viral entry
into the cell, such as heparin sulfate, NRP1, and Scavenger receptor class B member 1
(SRB1) (Cantuti-Castelvetri et al., 2020; Wei et al., 2020). Heparin sulfate binds to the S
protein and promotes viral infectivity (Q. Zhang et al., 2020). Similarly, the
overexpression of the SCARB1 gene, which encodes SRB1protein stimulates infection,
whereas its knockdown decreased the infection (Wei et al., 2020). Another receptor,
NRP1, binds to the CendR motif (RRARR) at the S1-S2 junction and increases SARSCoV-2 infectivity (Cantuti-Castelvetri et al., 2020).

2.3.5 SARS-CoV-2 Co-Receptor

AXL is a plasma membrane-associated member of the Tyro3/Axl/Mer (TAM)
family of tyrosine kinase receptors that regulate innate immunity and promote apoptotic
cell clearance (Morales et al., 2021). AXL was previously discovered to be a Zika virus
receptor, allowing the virus to enter human glial cells and facilitate infection by
downregulating interferon signaling. It also acts as a dengue virus entry factor and
enhances the entry of filoviruses. AXL has recently been identified as another important
entry receptor that stimulates the entry of SARS-CoV-2 into respiratory system cells. The
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association of the SARS-CoV-2 Spike protein's N-terminal domain (NTD) with AXL
enhances viral entry into human cells (S. Wang et al., 2021).

2.4 Discovery of OJT010 as a Novel Inhibitor of Severe Acute Respiratory Syndrome
Coronavirus 2

To limit the spread of COVID-19, new protective measures are needed to save the
lives of millions of people. This could be achieved quickly by repurposing old drugs to
accelerate drug discovery without lengthy preclinical and clinical studies. Previously
several research efforts have been made to repurpose old drugs against SARS-CoV-2.
Several clinical trials have been conducted to find effective measures to treat COVID-19.
Until March 2022, 7633 clinical trials have been registered to develop drugs and vaccines
for COVID 19 (Bugin & Woodcock, 2021). OJT010 is a demethylated metabolite of
OJT009. Both drugs are clinically approved mucolytic agents used to treat respiratory
diseases with excellent safety and tolerability (M & B, 2008). OJT010 has a wide range
of clinical properties, including secretolytic activity, anti-inflammatory, anti-antioxidant,
local anesthetic, antiviral, antibacterial, and antifungal (M & B, 2008; PR, 2010). It was
also recently reported that it is approved to treat COVID-19 in China (H et al., 2021).
Based on the plethora of preclinical and clinical evidence on its antiviral and antiinflammatory properties, we proposed that OJT010 might prevent or inhibit the entry and
replication of SARS-CoV-2.
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2.4.1 Primary Pharmacology of OJT010

The mechanism of action of OJT010 has been extensively investigated in multiple
studies. It has a broad range of effects, including mucokinetic properties, mucociliary
activity, and stimulation of surfactant production (H et al., 1987; K et al., 2006). It also
acts anti-inflammatory and antioxidant agent by balancing inflammatory reactions to
relieve symptoms of cough and cold. Its local anesthetic effect helps alleviate symptoms
of sore throat (D et al., 1994; KM et al., 2008; PR, 2010).

Apart from these, recent studies have drawn more attention to its role in the
autophagy-lysosomal pathway, a critical process for inhibiting viral proteins and further
dissemination (Magalhaes et al., 2018). Furthermore, OJT010 suppresses the influenza
virus's proliferation in the airway and improves mice's survival rate (B et al., 2002).
Additionally, OJT010 potentiates antibiotic activity in the lungs by increasing their
concentrations (M & B, 2008; R et al., 1987). It has gained attention due to its activity as
a GCase chaperone to treat neurodegenerative diseases (A et al., 2020).

More recently, it has been evaluated as an antiviral agent against SARS-CoV-2
for the potential treatment of COVID-19 (BF et al., 2021; SB et al., 2020). I will briefly
discuss the role of OJT010 in various diseases.
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Mucokinetic and Mucociliary Properties: SARS-CoV-2 infects mainly alveolar
Type 2 (AT2) epithelial cells in the lungs. AT2 plays an essential role in surfactant
production. OJT0010 increases surfactant production, ciliary activity, and bronchial
secretions, which aid in clearing viral particles (B et al., 2002; Z. P et al., 2020). It
accumulates in lamellar bodies (LB) found in AT2 cells and elicits calcium release from
lamellar bodies, which triggers the fusion of LB with the plasma membrane leading to
surfactant release (P & M, 2021). OJT010 has shown a dose-dependent increase in
surfactant production, thereby maintaining the alveolar function, and preventing an
alveolar collapse in vivo in rats, rabbits, guinea pigs, and ferrets (H et al., 1987; M & B,
2008).

Antioxidative and Anti-Inflammatory Activities: OJT0010 suppresses viral
proliferation by upregulating anti-inflammatory factors. In a mouse study of acute lung
injury, OJT0010 significantly reduced proinflammatory cytokines, such as tumor necrosis
factor-α (TNF-α), interleukin-6 (IL-6), and transformation growth factor-β1 (TGF-β1),
reduced lung inflammation and accelerated recovery from acute lung injury induced by
lipopolysaccharide (KM et al., 2008; X et al., 2004).

Moreover, OJT0010 inhibits histamine release, LTC4, IL-4, IL-13, and LTB4
from mast cells, basophils, and monocytes (BF et al., 1999). It decreases the
concentration of TNF-α, interleukin (IL)-2, IL-1, IL-4, IL-6, IL-13, interferon (IFN)-γ,
and TGF-β1 in the broncho-alveolar lavage (BF et al., 1999).
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Interestingly, it has high affinity for lung tissue, resulting in 20 times higher
concentration than blood after oral or IV administration with no toxicity (Choi et al.,
2018). It also acts as a free radical scavenger and decreases the release of reactive oxygen
species from polymorphonuclear and mononuclear cells, thus prevent against oxidative
damage (D et al., 1994). Moreover, co-treatment of OJT0010 with another antibiotic,
including beta-lactams, glycopeptides, macrolides, nitrofurans, and rifamycin’s, increases
their concentration in lung tissue and airway surface fluid levels (V & GS, 2019).

Local Anesthetic: OJT0010 is a potent inhibitor of neuronal voltage-gated Na+
and Ca+ channels (M & B, 2008). It acts as a chaperone and binds to the active site of
the GCase protein and reduces activity. The binding of OJT0010 to GCase enables its
transportation to the lysosome and release of free active enzymes under acidic conditions.
In other tissues, such as the brain, OJT0010 increases intracellular GCase activity, as
reported in studies of rodent and primate models (GH et al., 2009).

Effect on Autophagy: The autophagy and lysosome systems play a crucial role in
clearing viral infections. OJT0010 induces autophagy in a dose-dependent manner and
mycobacterial death in macrophages. Also, potentiate rifampin activity through an
unclear mechanism (Magalhaes et al., 2018; SW et al., 2018)

Ion Homeostasis: OJT010 modulates chloride ion conductance in cystic fibrosis.
At 100 µM, it increases chloride transport across the apical cell membrane of
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immortalized cells. A maximum increase in chloride conductance (~8 fold) was seen after
8 h of treatment with OJT010 compared to control (G et al., 2013).

Effect Viral Infection: OJT0010 reduced RV14 infection-induced production of
mediators, including IL-1β, IL-6, and IL-8. It significantly reduced the levels of the p50
and p65 subunits of nuclear factor kappa B (NF-κB). Furthermore, it reduced the number
and fluorescence intensity of acidic endosomes from which RV RNA enters the
cytoplasm (C et al., 2020; M et al., 2014).

OJT0010 significantly suppressed the influenza-virus multiplication in the airway
of mice and improved the survival rate. Furthermore, it stimulated pulmonary surfactant
release, mucus protease inhibitor, immunoglobulin (Ig)-A, and IgG (B et al., 2002; C et
al., 2020).

OJT010 is an active demethylated metabolite of OJT009. Both drugs act as
mucolytic agents and are widely available over the counter in many countries to treat
upper respiratory tract diseases with proven efficacy and safety (D et al., 1987; H et al.,
1987; KM et al., 2008; S et al., 1997). OJT009 has been hypothesized to inhibit one of
the critical host proteases, TMPRSS2, involved in the SARS-CoV-2 infection pathway
(JM et al., 2014). TMPRSS2, an androgen-regulated cell surface serine protease, cleaves
the spike protein to aid viral and cell membrane fusion (Hoffmann et al., 2020).
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Olaleye et al. discovered for the first time that OJT010 and its progenitor OJT009
inhibit the SARS-CoV-2 infection-induced cytopathic effect at micromolar concentration.
In addition, OJT010 and OJT009 effectively modulated the binding between RBD and
ACE2 (Olaleye et al., 2020). Lucas et al. discovered OJT009 in a chemical screen to
identify a potent, bioavailable TMPRSS2 inhibitor suppressing prostate cancer metastasis
in vivo (JM et al., 2014). Because of its activity on TMPRSS2, OJT009 is tested in
clinical trials against COVID-19. Because of the parent drug, OJT010 was hypothesized
to have activity against TMPRSS2 and therefore proposed for further studies to identify
its role against SARS-CoV-2 (Li, 2020). There are only a few reports published regarding
the role of these two compounds against SARS-CoV-2 infection. In this study, we
focused on OJT010, and I will briefly discuss what has already been known about its
anti-SARS-CoV-2 activity in the literature.

A study published by Bradfute et al. evaluated the effects of OJT009 and
OJT0010 against SARS-CoV-2 in Vero E6 cells. The method used to determine the
activity of compounds were cell survival assay, quantitative PCR, and plaque-forming
assay. In the cell survival assay, 0JT009 had no inhibition of viral infection at 1, 10, and
100 µM (SB et al., 2020). OJT010 showed a dose-dependent increase in cell survival
with maximum activity at 100 µM. High concentrations of OJT010 has been
demonstrated safe in long-term use in Parkinson’s disease, pregnant women, and Gaucher
disease, and doses of this magnitude are known to lead to lung levels approaching 100
μM (GH et al., 2009; I et al., 2013). Furthermore, high dose OJT0010 has been shown
both safe and effective in reducing inflammatory cytokines (TNF-a and IL-1, IL-6, Nf-
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kB) and improve the course of respiratory disorders such as acute respiratory distress
syndrome (ARDS) (K et al., 2006).

Another study evaluated the effect of OJT009 and OJT0010 on the cell-cell fusion
induced by SARS-CoV-2 infection in vitro. OJT009 induced SARS-CoV-2 expression
when ACE2 and TMPRSS2 were present together in a dose-dependent manner. At the
same time, OJT0010 did not lead to enhancement but a slight decrease in activity at 50
μM (BF et al., 2021).

A study done by Carpinteria et al. discovered the role of OJT010 as an inhibitor of
acid sphingomyelin. Their study identified the role of acid sphingomyelin as an activator
of the spike protein. Acid sphingomyelins stimulate the release of ceramides, which
promotes viral infections. Inhalation of 20 mM of OJT010 solution decreases
sphingomyelin/ceramide activity in nasal epithelial cells, preventing the entry of spike
pseudovirus into the cell (A et al., 2021).

2.4.2 Toxicology of OJT010 in Animals

In single-dose toxicity trials (mouse, rat, rabbit, guinea pig, and dog), OJT010 was well
tolerated after oral and parenteral administration (Y et al., 2022). Subacute and chronic
oral repeated toxicology studies in rat, rabbit, guinea pig, and dog for a period ranging
from 26 weeks to 78 weeks showed little to no adverse effects and negligible signs of
target organ toxicity with doses up to 2500 mg/kg (rat) and 250 mg/kg (rabbit and dog)
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(M & B, 2008). Clinical symptoms of toxicity following overdoses across species were
body weight loss, dyspnoea, reduced motoric activity, ataxia, and convulsions. All
adverse effects were reversible, and there was no evidence of progression (Y et al., 2022).

The minimum tolerated dose without any adverse effects were 50 mg/kg (rat), 40 mg/kg
(rabbit) and 10 mg/kg (dog). Oral doses of OJT010 in rats and rabbits of up to
3000mg/kg and 200mg/kg respectively did not impair early embryonic development.
There was no evidence for any embryotoxicity or teratogenicity. Similarly, there was no
evidence for a treatment-related tumorigenic potential of OJT010 in mice and rats (H et
al., 2022). Overall, OJT010 is an extensively investigated drug with a well-established
favorable safety profile in animals, verified by its widespread therapeutic use in humans
over the past decade.

2.4.3 Pharmacokinetics and Metabolism of OJT010

The pharmacokinetics of OJT010 has been extensively studied in the mouse, rat,
rabbit, and dog. In both animals and humans, gastrointestinal absorption of OJT010 is
quick and nearly complete. In humans, absolute oral bioavailability is high, whereas, in
animals, it is lower. The rapid and extensive distribution of OJT010 is consistent with its
high volume of distribution. It is rapidly and extensively distributed from the blood into
tissues.
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OJT010 is substantially metabolized into DBAA in animals and humans (3,5
dibromoanthranilic acid). DBAA has a low tissue distribution compared to the parent
molecule. Across species, plasma protein binding for OJT010 is low but very strong for
its metabolite DBAA. OJT010 has a short half-life in mice and dogs but a moderate halflife in rats and humans.

2.4.4 Clinical efficacy of OJT010

OJT010 is used antenatal and post-natal in newborns to prevent infant respiratory
distress syndrome (IRDS) and fetal lung maturity. Healthy pregnant women (24-34
weeks) were given one-two dose of (1g-1.3g) of OJT010 daily, oral or I.V infusion for 15 days. Administration of OJT010 to pregnant did not cause any toxicity (M et al., 1987;
Paleari et al., 2011). The only reported side effects were nausea and headache. The
number of pregnant women enrolled in the study ranged between 20-300 in number.
Antenatal uses of OJT010 resulted in a significant decrease in the incidence of IRDS and
prenatal morbidity and mortality (C et al., 1997; Y et al., 1995).

OJT010 was highly safe when used in infants with IRDS during the first five days
at a dose of 20-30mg daily and reduced the incidence of IRDS associated complications
(A et al., 1987; RR et al., 1992). OJT010 administration in the adult population with
chronic obstructive lung disorders and lung carcinomas requiring surgeries due to
thoracic pathologies or patients with spinal cord injuries has significantly prevented
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postoperative complications and improved airway patency in patients with chronic
obstructive pulmonary disease (COPD) (E et al., 1994; G, 1991; P & P, 1989). OJT010
was dosed at 1g per day through I.V infusion for the duration of 3-5days. Similar to
pregnant women, no significant toxicity was reported by this group. Patients enrolled in
the study were between 20-250 in number (E et al., 1994; G, 1991; P & P, 1989).

OJT010 has been extensively studied to prevent and exacerbate upper respiratory
diseases, mainly in adults. Long-term use of high-dose OJT010 has reduced the severity
and frequency of upper respiratory disorders. Most studies included a population with
chronic bronchitis and were treated with a dose of 45- 150mg/day orally from 10-days to
1 year (CH et al., 1987; E et al., 1994). No significant adverse effects were reported
during treatment with the drug. Use of OJT010 has shown no toxicity when used at doses
of 10-270 mg daily orally for a duration of 10 days to 17 months for the treatment of
diseases such as Gaucher’s disease, radiation lung injury, sore throat, cystic fibrosis,
primary Sjogren’s syndrome, secretory otitis media (CH et al., 1987; E et al., 1994).

CHAPTER 3
DESIGN OF THE STUDY

3.1 Central Hypothesis and Specific Aims

OJT010 is an orally bioavailable drug with broad-spectrum antiviral activity
against rhinovirus and influenza virus (B et al., 2002). It inhibits viral replication by
suppressing the release of inflammatory cytokines and reducing the activation of
transcription factor nuclear factor kappa B (NF-kB) (B et al., 2002). Moreover, it has
been shown to decrease the expression and protein levels of intercellular adhesion
molecule-1 (ICAM-1), a receptor for rhinovirus (M et al., 2014). Also, it reduces the
number of acidic endosomes from which the virus enters the host cytoplasm (C et al.,
2020; M et al., 2014). Furthermore, OJT010 plays an essential role in the homeostasis of
the chloride ions (G et al., 2013). ACE2 has a chloride binding site, and it is essential for
substrate hydrolysis. It also plays an essential role in determining the structural
conformation of ACE2, which makes it receptive to binding with RBD of Spike protein
(Towler et al., 2004; Vickers et al., 2002). Therefore, modulation of chloride ions by
OJT010 may prevent the binding of ACE2 to the SARS-CoV-2 spike protein. In our
efforts to identify clinically approved drugs for the potential treatment of COVID-19, our
laboratory conducted a screen for inhibitors of SARS-CoV-2 infection. We discovered
three compounds that inhibited the SARS-CoV-2 infection-induced cytopathic effect and
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had potent activity against ACE2-RBD interaction. These compounds were
structurally similar to OJT010. We hypothesize that OJT010 interaction with ACE2 will
block viral entry and inhibit the replication of SARS-CoV-2 in vitro.
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3.2 Specific Aim 1: To Evaluate the Efficacy and Cytotoxicity of OJT010 against
SARS-CoV-2 Infection.
3.2.1 (1a) To Determine the Antiviral Activity of OJT010 against SARS-CoV-2
and its Delta Variant B.1.617.2

Rationale: COVID-19, caused by the deadliest SARS-CoV-2, represents a big
challenge for the health care system. The scientific community has made numerous
efforts to discover drugs that can inhibit the replication of SARS-CoV-2. Repurposing
clinically approved drugs is an accelerated pathway to solving the unprecedented
situation created by this pandemic. Through a focused search of clinically approved drugs
that have activity against SARS-CoV-2, our lab discovered OJT010 as a novel inhibitor
of SARS-CoV-2 infection. In this study, we evaluated the efficacy of OJT010 against
viral replication using three independent in vitro assays.

3.2.2 (1b) To Assess the Cytotoxicity of OJT010 in VeroE6 Kidney and A549
Lung Cells.
Rationale: To determine the effective concentrations against SARS-CoV-2, first,
we evaluated the cytotoxicity of OJT010 in the mammalian cell lines. Concentration
below the CC50 was used in the antiviral assay to determine IC50 of OJT010 against
SARS-CoV-2. This ensures that the response obtained in the antiviral assay is due to the
direct activity of OJT010 against the virus, not due to the cytotoxic effects on the cells.
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3.2.3 (1c) To Determine the Efficacy of the Combination of OJT010 with
Remdesivir against SARS-CoV-2 in vitro

Rationale: Till now, remdesivir is the only FDA-approved drug for the treatment
of COVID -19. However, the clinical efficacy of remdesivir is controversial (Grein et al.,
2020). Moreover, a combination of drugs has been used to treat COVID-19 (@US_FDA,
2020; Consortium et al., 2021). In the absence of potent single-agent therapy against
SARS-CoV-2, new drugs that could potentiate the activity of already approved antiviral
can significantly speed up the clearance of the virus and decrease hospitalization and
death. Therefore, we evaluated the effects of OJT010 on remdesivir and vice-versa
against SARS-CoV-2.
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3.3 Specific Aim 2: To Investigate and Characterize the Impact of OJT010 on the
Interaction of rhACE2 and RBD of SARS-CoV-2 and the Exopeptidase Activity of
ACE2.
3.3.1 (2a) To Evaluate the effects of OJT010 on the Interaction of rhACE2 and
RBD of SARS-CoV-2

3.3.2 (2b) To Determine whether OJT010 Impacts the Exopeptidase Activity of
ACE2

Rationale: Interaction of ACE2 with RBD of Spike protein is the most crucial
step in the viral life cycle. In addition to direct viral effects, downregulation of ACE2 by
SARS-CoV-2 creates an imbalance between the RAS and ACE2/angiotensin (1-7) axis,
which further contributes to inflammation and multiple organ injury in COVID-19 (SN et
al., 2021). Drugs that can block the interaction between these two proteins will inhibit the
entry of SARS-CoV-2 into the cells. This will prevent the infection and damage caused to
the host cell by over-activating the immune system in response to the virus challenge.

3.2.3 (2c) To Investigate Binding Sites for OJT010 on the SARS-CoV-2 and Host
ACE2 Receptor Through Computational Studies.

Rationale: To understand the molecular mechanism of action of OJT010, we
determined the binding amino acid residues for the active sites on the viral and host
receptor by molecular docking. Understanding the mechanism of action will provide
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insight into the new possible means of OJT010 other than the already known in the
literature. Furthermore, this will guide developing an effective treatment plan for OJT010
as a prophylactic or therapeutic agent for the treatment of COVID 19.

3.4 Specific Aim 3: To Determine the In Vivo Pharmacokinetic Parameters of OJT010
in Healthy rats.

Rationale: To advance into in vivo efficacy models and clinical studies, it is
essential to understand the time course of drug concentration in the body.
Pharmacokinetic and pharmacodynamic (PK/PD) studies in drug discovery and
development are vital to translate the preclinical IC50 into clinical efficacies. We
determined the PK parameters of OJT010 in healthy rats to understand target drug
exposure and drug disposition.
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3.5 Materials and Methods for Pharmacological Studies

Drugs: OJT010 and Dimethyl sulfoxide (DMSO) (D8418-1Lot#SHBM4129)
were purchased from Sigma Aldrich (St. Louis, MO). OJT010 was dissolved in 100 %
DMSO at a concentration of 50mM and was further serially diluted in 100% DMSO.

3.5.1 COVID-19 Spike-ACE2 Binding Assay Kit

A Spike (RBD) - ACE2 binding assay kit (Cat # CoV-SACE2-1, Lot# 062320
7066) was purchased from RayBiotech (RayBiotech, 2022). The enzyme-linked
immunoabsorbent assay (ELISA) was performed in a transparent flat-bottom 96-well
plate, following manufacturer instructions. We prepared 10 mM stock solutions of the
compounds in DMSO and serially diluted the compounds in DMSO as follows: 100, 50,
10, 5, 1, 0.5, and 0.1 μM for OJT009 and OJT010. All experiments were done in
triplicates and repeated thrice. Each plate contained a positive control (1% DMSO) and a
blank control with no ACE2.

Briefly, 96 well plate pre-coated with recombinant SARS-CoV-2 Spike receptorbinding domain (RBD) protein was incubated 1μL of serially diluted compounds in 49
μL of 1X assay diluent buffer for a duration of 30 mins, at room temperature (22°C) with
shaking at 180rpm. After this, 50 μL of ACE2 protein in 1X assay diluent buffer was
added into the 96 well plates, and the reaction was allowed to go on for 2.5 hr at room
temperature (22°C) with shaking at 180rpm. After that, the reaction mixture was
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discarded, and the plate was washed consecutively four times with 300μL 1X wash
buffer, followed by the addition of the detection antibody (anti-ACE2 goat antibody)
further incubated for one hr at room temperature (22°C) with shaking at 180rpm. Then,
the solution was discarded, and the plate was washed as described above.

In the next step, the HRP-conjugated anti-goat IgG was added to each well, and
the reaction plates were further incubated for 1 hr at room temperature (22°C) with
shaking at 180rpm. Again, the solution was discarded, and the final wash step was
repeated as described above. in the final step, 100 μL of 3,3’,5,5’-tetramethylbenzidine
(TMB) one-step substrate was added to the reaction mixtures and incubated in the dark at
room temperature (22°C) with shaking at 180rpm for an additional 30 mins and then
stopped by the addition of 50μL stop solution. The absorbance was read immediately at
405 nm using a Beckman Coulter DTX880 multimode plate reader. The data were fitted
after the background hydrolysis was adjusted using a special bell-shaped dose-response
curve equation in GraphPad prism software 8.4.3.

3.5.2 ACE2 Inhibitor Screening Assay

An ACE2 exopeptidase Inhibitor screening assay kit with the fluorogenic
substrate (Catalogue #79923) was purchased from BPS Bioscience (San Diego, CA) and
modified to measure the exopeptidase activity of ACE2 in the presence and absence of
inhibitors (BPSBioscience, 2022). Following the manufacturer's directions, the
fluorescence assay was carried out in a 96-well black flat-bottom plate with a final
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reaction volume of 50 μL. We prepared 50 mM stock solutions of OJT009 and OJT010 in
100% DMSO. We further serially diluted the compounds in DMSO as follows: 500, 250,
100, 50, 10, 1, 0.1 μM. All experiments were done in triplicates and repeated twice. A
positive control of enzyme treated with vehicle alone (2 percent DMSO) and a blank
control with no enzyme were included on each plate.

Briefly, each reaction had 24 μL of purified recombinant human ACE2 protein
(0.42ng/μL) in ACE2 buffer, one μL of the compound at different concentrations, and 25
μL ACE2 fluorogenic substrate. The final volume of the reaction was 50 μL. The reaction
mixtures were incubated for 1 hrs at room temperature (22 C) and protected from light.
After that, the fluorescence intensities (λExcitation = 535nm, λEmission = 595nm) were
measured using a Spectramax iD3 multimode plate reader. The background hydrolysis
was subtracted, and the data were fitted to a four-parameter logistic (variable slope)
equation using GraphPad prism software 9.1.

3.5.3 ACE 1 Exopeptidase Activity

ACE1 Inhibitor Screening Kit (Cat #MAK422) was purchased from Sigma-Aldrich (St.
Louis, MO) and adapted to determine the effect of OJT010 on the enzymatic activity of
ACE (Aldrich, 2022). The in vitro colorimetric assay was performed in a transparent flatbottom 96-well plate. We prepared 50mm and 10mm solutions of Captropil, a known
ACE1 inhibitor used as a positive inhibitor control. Stock solutions of the compounds
were prepared in 100 % Dimethyl sulfoxide (DMSO) and further serially diluted in
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DMSO as follows: 500, 100, 50,10,5,1 and 0.5 µm for OJT010 and the positive control
Captropil. All experiments were performed in Quadruplicates. Each plate contained a
positive control (1% DMSO) and a blank controls with no ACE1 enzyme. Specifically,
2.5 µl of serially diluted compounds were pre-incubated with 2µl of ACE1 protein
diluted in 38 µl of 1X assay diluent buffer for about 15 mins, at room temperature
(22°C). Then, we added 157.5µl of 1x ACE1 assay buffer (197.5µl for -ve control) into
the 96 well plates. The solution was mixed well and incubated at 37 °C for 15-20
minutes, protected from light. After that, 40µl of the substrate was added to each well and
mixed well. The absorbance was measured immediately at 345 nm (A345) in kinetic
mode for 60 minutes.

3.5.4 Material and Methods for Pseud typed Lentivirus Assay

Cell growth conditions and Medium, ACE2 Human Kidney 293 recombinant
Cells (ACE2 HEK-293-#79951), Thaw media (#60187-1), Growth media (#79801),
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter # 79942), Spike S1
Neutralizing Antibody (# 101024), and ONE-Step™ Luciferase Assay System (#606901) were purchased from BPS Biosciences (San Diego, CA). The pseudotyped lentivirus
contained SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) and the
firefly luciferase gene under the control of the CMV promoter. Expression of luciferase
can be detected after the addition of the substrate. When pseudovirions are incubated with
a molecular inhibitor before infection, they will block the spike-mediated cell entry. The
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number of blocked viruses can be measured via luciferase reporter activity. (Nie et al.,
2020)

Briefly, HEK293 cells were resuspended in thaw media (no puromycin) and
cultured in a T25 flask at 37°C in a CO2 incubator. After the first passage, cells were
further cultured in growth media (contains puromycin). On the experiment day, ACE2HEK293 were seeded at the density of 7500 cells per well into a white opaque 96-well
cell culture microplate in 90 μl of growth medium. Cells were inoculated with 750
infectious particles (MOI =0.1) of SARS-CoV-2. Before infection, pseudotyped
lentivirus (5μl) was preincubated with OJT010 (5μl) at concentrations ranging from 100,
50, 25, and 10 μM and with controls for 30 minutes at room temperature (RT); the
reactions were then added to the cells. After 48 hours, 100 μl Luciferase reagent (BPS
Bioscience, catalog no. 60690) was added to measure luciferase activity. Luminescence
was measured with Spectra max ID3 (molecular devices). The measured luminescence
signal was directly proportional to the amount of Pseudo typed lentivirus successfully
transduced into the cells. Data are presented as percent inhibition of entry of pseudo-type
lentivirus into the HEK293-ACE2 cells (Bioscience, 2022). Infected cells and infected
treatment cells (Spike neutralizing antibodies) were positive and negative controls. All
experiments were done in duplicates and were repeated twice.
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3.5.6 Antiviral assays using SARS-CoV-2 In Vitro

Screening Strategy: We will employ a cell-based assay measuring the cytopathic
effect (CPE) of the virus infecting Vero E6 host cells. The CPE reduction assay is a
popular and widely used assay format to screen for antiviral drugs because of its ease of
use in the high throughput screening (HTS) (CB et al., 2008; WE et al., 2007). In this
assay, host cells infected with the in this assay, virus-infected host cells die as a result of
the virus's hijacking of cellular mechanisms for replication processes. By monitoring the
viability of host cells three days after virus inoculation, the CPE reduction assay
indirectly measures the effect of antiviral drugs acting through various molecular
mechanisms. Anti-viral compounds are identified as those that protect the host cells from
the cytopathic effect of the virus, thereby increasing viability.

3.5.7 Infection Induced Cytopathic Effect (CPE)

Vero E6 cells selected for expression of the SARS CoV receptor (ACE2;
angiotensin-converting enzyme 2) are used for the CPE assay(W et al., 2003). Cells are
grown in MEM/10% HI FBS supplemented and harvested in MEM/1% PSG/
supplemented 2% HI FBS. Cells are batch inoculated with either SARS CoV-2 (M.O.I. ~
0.002), resulting in 5% cell viability 72 hours post-infection. Compound samples are
serially diluted 2-fold in DMSO nine times. Assay Ready Plates (ARPs; Corning
3712BC) pre-drugged with test compounds (90 nL sample in 100% DMSO per well
dispensed using a Labcyte ECHO 550) are prepared in the BSL-2 lab by adding 5μL
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assay media to each well. The plates are passed into the BSL-3 facility, where a 25μL
aliquot of virus inoculated cells (4000 Vero E6 cells/well) is added to each well in
columns 3-22. The wells in columns 23-24 contain virus-infected cells only (no
compound treatment). Before virus infection, a 25μL aliquot of cells is added to columns
1-2 of each plate for the cell only (no virus) controls. Plates were incubated at
37°C/5%CO2 and 90% humidity for 72 hours, and then 30μL of Cell Titer-Glo
(Promega) is added to each well.

Luminescence is read using a Perkin Elmer Envision or BMG CLARIOstar plate
reader following incubation at RT for 10 minutes to measure cell viability. Raw data
from each test well is normalized to the average signal of non-infected cells (Avg Cells;
100% inhibition) and virus-infected cells only (Avg Virus; 0% inhibition) to calculate %
inhibition of CPE using the following formula: % inhibition = 100*(Test Cmpd - Avg
Virus)/(Avg Cells – Avg Virus). The SARS CPE assay is conducted in BSL-3
containment with plates being sealed with a clear cover and surface decontaminated prior
to luminescence reading (CB et al., 2008; W et al., 2003; WE et al., 2007).

3.5.8 Cytotoxicity of OJT010 in CPE Assay

Compound cytotoxicity is assessed in a BSL-2 counter screen as follows: In each
well of assay-ready plates prepared with test compounds as described above, host cells in
media are added in 25 μl aliquots (4000 cells/well). Cells alone (100 percent viability)
and cells treated with hyamine at a final concentration of 100M (0 percent viability) serve
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as the high and low signal controls for cytotoxic effect in the assay, respectively. The
DMSO concentration is kept constant in all wells (0.3 percent), as determined by the
dilution factor of stock test compound concentrations. After 72 hours of incubation at
37°C/5 percent CO2 and 90% humidity, 30μl Cell Titer-Glo (Promega) is added to each
well. Following a 10-minute incubation at room temperature, Luminescence was
measured using a BMG PHERAstar plate reader to measure cell viability.

3.5.9 Nano luciferase Reporter Virus Assay

A549 cells expressing ACE-2 (obtained from Ralph Barric at UNC) are grown in
DMEM high glucose supplemented with 20% HI FBS, 1% NEAA, 100 µg/ml Blasticidin
and split 1:6 every three days (remove Blasticidin from the media one passage before
using the cells in the assay). On the day of assay, the cells are harvested in DMEM
supplemented with 2% HI FBS, 1% HEPES, 1% Pen/Strep. Assay-ready plates predrugged with test compounds are prepared in the BSL-2 lab by adding 5μL assay media
to each well. The plates and cells are then passed into the BSL-3 facility. A working
stock of SARS CoV-2 nanoluciferase reporter virus (NLRV) passaged five times in A549
cells expressing ACE2 is diluted 6000-fold in media containing 160,000 cells per mL
(MOI ~ 0.002) and stirred at 200 RMP for approximately 10 minutes. A 25μL aliquot of
virus inoculated cells (4000 cells) is added to each well in columns 3-24 of the assay
plates. The wells in columns 23-24 do not contain test compounds, only virus-infected
cells for the 0% inhibition controls. Prior to virus inoculation, a 25μL aliquot of cells is
added to columns 1-2 (no test compounds) of each plate for the cell, only 100% inhibition
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controls. After incubating plates at 37°C/5%CO2 and 90% humidity for 72 hours, 30μL
of NanoGlo (Promega) is added to each well. Luminescence is read using a BMG
CLARIOstar plate reader (bottom read) following incubation at room temperature for 10
minutes to measure luciferase activity as an index of virus titer. Plates are sealed with a
clear cover and surface decontaminated prior to luminescence reading (B et al., 2015).

3.5.10 Cytotoxic effect of OJT010 in NLRV assay

Compound cytotoxicity is assessed in a BSL-2 counter screen as follows: In each
well of assay-ready plates prepared with test compounds as described above, host cells in
media are added in 25 μl aliquots (4000 cells/well). Cells alone (100 percent viability)
and cells treated with hyamine at a final concentration of 100M (0 percent viability) serve
as the high and low signal controls for cytotoxic effect in the assay, respectively. The
DMSO concentration is kept constant in all wells (0.3 percent), as determined by the
dilution factor of stock test compound concentrations. After 72 hours of incubation at
37°C/5 percent CO2 and 90% humidity, 30μl Cell Titer-Glo (Promega) is added to each
well. Following a 10-minute incubation at room temperature, Luminescence was
measured using a BMG PHERAstar plate reader to measure cell viability.
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3.5.11 The Effect Synergism of OJT010 with Remdesivir on SARS-CoV-2 Infection

Compounds were tested in a dual combination design in the CPE and NLRV
assays. The only difference in the experiment was the compound layout and data
analysis.

Each combination consisted of seven concentrations of one compound (cmpd B)
across a section of the plate with seven concentrations of the second compound (cmpd A)
arranged down the same plate section as shown below. Compounds were run in anti-viral
and cytotoxicity assays when tested. Serial dilutions were performed to produce 6X
concentrations such that a 5 µL transfer into the assay resulted in the final concentrations
indicated (30 µL total assay volume).
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Figure 7: Method for Measuring the Effect of Combination Therapy of OJT010
and Remdesivir (A=OJT010, B=Remdesivir)
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3.5.12 Data analysis

The raw data from plate readers are imported into the activity base for all assays,
where raw values are associated with compound IDs and test concentrations.
For the antiviral NLRV assay, raw signal values are converted to % inhibition by the
following formula:
% inhibition = 100 x (test compound value – mean value infected cell controls)/(mean
value uninfected cell controls – mean value infected cell controls).
For the cell viability assay measuring compound cytotoxicity, % cell viability is
calculated as follows:
% viability = 100*(test compound value - mean low signal control)/(mean high signal
control – mean low signal control).
EC50 and CC50 values are calculated from a four-parameter logistic fit of data using the
Xlfit module of Activity base with top and bottom constrained to 100 and 0%,
respectively.
Concentration-response graphs of compound combinations were produced in the
Graphpad Prism software package.

For synergy analysis, reduced data with associated concentrations and compound
ids were imported into, which applies models for detection of synergistic interactions.
The zero-interaction potency (ZIP) model was used.
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3.6 Methods for Molecular Docking and Simulation Study
3.6.1 Protein (hACE2-RBD) Acquisition and Preparation

The X-ray crystal structures of the complex of SARS-CoV-2 RBD with hACE-2
(Wild-type (WT)) (PDB code: 6LZG) and Delta variant (PDB ID: 7DF4) were obtained
from the RSCB Protein Data Bank (C et al., 2021; Q. Wang et al., 2020). The protein
structures were then prepared on the UCSF Chimera software package (Z et al., 2012).
The structures of the proteins were prepared by removing water molecules, nonstandard
naming, protein residue connectivity. The mucolytic drug (OJT010) was accessed from
PubChem (S et al., 2016). The 3-D structures of the drugs were prepared on the Avogadro
software package (Hanwell et al., 2012).

3.6.2 Molecular Docking between Proteins and Drug

For molecular docking, Chimera's Autodock was utilized with default docking
parameters (O & AJ, 2010), The drug molecules were given Gasteiger charges before
docking, and the non-polar hydrogen atoms were fused into carbon atoms. The molecules
were then docked first into the hACE-2 catalytic binding pocket, and secondly, at the
hACE-2-RBD binding site by defining the grid box with a spacing of 1 Å each and size
and (22 × 18 × 22) and (32 × 41 × 25) pointing in x, y and z directions, respectively. The
best docking poses for the two drugs were then subjected to molecular dynamics
simulations.
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3.6.3 Molecular Docking between ACE2-Spike protein
For the protein-protein molecular docking, the Haddock (High Ambiguity Driven
Protein-Protein Docking) server was employed, which uses biochemical or biophysical
interact data such as chemical shift perturbation data from NMR titration experiments or
mutagenesis data (Cyril Dominguez et al., 2003). The binding residues on the two proteins
were specified, and all other parameters were left at default settings.

3.6.4 Molecular Dynamic (MD) Simulations
The MD simulation was carried out in the manner outlined by Kehinde et al (I et
al., 2019). The simulations were run on the GPU version of the AMBER package (AMBER
18), with the FF18SB variant of the AMBER force field utilized to describe the systems
(PC & JO, 2014).
The Restrained Electrostatic Potential (RESP) and General Amber Force Field
(GAFF) techniques were employed in ANTECHAMBER to create atomic partial charges
for the ligand. AMBER 18's Leap module permitted the addition of hydrogen atoms and
Na+ counter ions to the ACE2-RBD complex in order to neutralize all systems. The
systems were then implicitly suspended within an orthorhombic box of TIP3P water
molecules, with all atoms within 10 of any box edge (Jorgensen et al., 1998).
For both solutes, an initial minimization of 2000 steps was performed with a
restraint potential of 500 kcal/mol imposed. They were completed in 1000 steps using the
steepest descent method, followed by 1000 steps of conjugate slopes. An extra full
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minimization of 1000 steps was performed using the conjugate gradient approach with no
constraints. For 50 ps, a gradual heating MD simulation from 0 to 300 K was run, ensuring
that the systems maintained a fixed number of atoms and a fixed volume. The systems'
solutes were subjected to a potential harmonic constraint of 10 kcal/mol and a collision
frequency of 1.0 ps. Following heating, each system was subjected to a 500-ps
equilibration, with the operating temperature held constant at 300 K. Additional
characteristics, such as numerous atoms and pressure, were also kept constant, simulating
an isobaric-isothermal ensemble. The Berendsen barostat was used to keep the system
pressure at 1 bar (Basconi & Shirts, 2013; GonnetPedro, 2007).
The entire time spent on the MD simulations was 100 ns. The SHAKE algorithm
was used in each simulation to constrict hydrogen atom bonds (Ryckaert, 2022; Ryckaert,
J.P., Ciccotti, G. and Berendsen, H.J. (1977) Numerical Integration of the Cartesian
Equations of Motion of a System with Constraints Molecular Dynamics of n-Alkanes.
Journal of Computational Physics, 23, 327-341. - References - Scientific Research
Publishing, 2022).
Each simulation employed a 2fs step size and an SPFP accuracy model. The
simulations matched the isobaric-isothermal ensemble (NPT) with randomized seeding, a
constant pressure of 1 bar maintained by the Berendsen barostat (Basconi & Shirts, 2013),
a pressure-coupling constant of 2 ps, a temperature of 300 K, and a Langevin thermostat
(GonnetPedro, 2007) with a collision frequency of 1.0 ps.
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3.6.5 Post-Dynamic Analysis
3.6.5.1 Binding Free Energy Calculations
The Molecular Mechanics/GB Surface Area approach (MM/GBSA) was used to
compute the free binding energy (Ylilauri & Pentikäinen, 2013). Binding free energy was
averaged across 100000 snapshots taken from the 100ns trajectory. This approach
computes the free binding energy (ΔG) for each molecular species (complex, ligand, and
receptor) as:
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The gas-phase energy is denoted by Egas, which is made up of the internal energy Eint,
the Coulomb energy Eele, and the van der Waals energies Evdw. The Egas was calculated
directly from the FF14SB force field terms. The energy contribution from the polar states,
GGB, and non-polar states, Gsol, were used to calculate the solvation free energy, Gsol.
Using a water probe radius of 1.4, the non-polar solvation energy, SA. GSA, was calculated
from the solvent-accessible surface area (SASA). In contrast, the contribution of the polar
solvation, GGB, was determined by solving the GB equation. S and T signify the solute's
total entropy and temperature, respectively.

70
3.7 Materials for Pharmacokinetic Study

3.7.1. Chemicals and Drugs

•

Acepromazine (10 mg/mL) injection, purchased from Hospira (Lake Forest, IL),
was used as part of the anesthetic cocktail for jugular vein cannulation surgery.

•

Bupivacaine HCl injection USP (0.5%, 5mg/mL), purchased from Hospira (Lake
Forest, IL), was used to provide post-surgery analgesia to the animals.

•

Deionized water, produced in the lab with a Barnstead TM Smart2Pure TM water
purification system (Thermo Fisher Scientific, Waltham, MA), was used in
OJT010 formulation.

•

Formic Acid, purchased from Sigma-Aldrich (St. Louis, MO), was used to
enhance the ionization of OJT010 in the LC-MS/MS method development.

•

Heparin sodium injection (1000 units/mL), purchased from Hospira (Lake Forest,
IL), was used as anticoagulant in animal experiments.

•

Ketamine injection (100 mg/mL), purchased from Hospira (Lake Forest, IL), was
used as part of the anesthetic cocktail for jugular vein cannulation surgery.

•

LC-MS grade acetonitrile, purchased from J.T. Baker Chemical Co. (Phillipsburg,
NJ), was used to prepare mobile phase for the quantification of OJT010 by LCMS/MS.

•

LC-MS grade water, purchased J.T. Baker Chemical Co. (Phillipsburg, NJ), was
used to prepare mobile phase for the quantification of OJT010 by LC-MS/MS.
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•

LC-MS grade methanol, procured from Mallinckrodt Baker (Phillipsburg, NJ,
USA), was used for solubility studies of OJT010.

•

OJT010 (purity ≥ 98%) was purchased from Thermofisher (Tewksbury, MA)

•

Sodium chloride solution, 0.85 %, (normal saline) purchased from Sigma-Aldrich
(St. Louis, MO), was used to dilute dosing solutions for animal dosing.

•

OJT010-d5, purchased from Cayman Chemical (Ann Arbor, MI), was used as
internal standard (IS) for LC-MS/MS method.

•

Xylazine injection (100 mg/mL), purchased from Hospira (Lake Forest, IL), was
used as part of the anesthetic cocktail for jugular vein cannulation surgery.

3.7.2 Supplies

•

1 cc sterile tuberculin slip tip syringes and PrecisionGlide® 23 G TW needles,
purchased from Becton Dickinson & Co. (Franklin Lakes, NJ), were used during
animal experiments for intra-venous dosing and blood sampling.

•

Auto-sampler propylene injection vials (Clear; 100 µL), purchased from
ChromTech (Apple Valley, MN), were used to hold samples for injection in the
LC-MS/MS assays.

•

Auto-sampler propylene injection vials (Clear; 100 µL), purchased from
ChromTech (Apple Valley, MN), were used to hold samples for injection in the
LC-MS/MS assays.
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•

Cotton tipped applicators (6”), purchased from Baxter Healthcare Co (McGaw
Park, IL), were used during animal surgeries to stop bleeding and apply topical
contents during surgery.

•

Face masks, purchased from AlphaProTech, Inc. (Salt Lake City, UT), were worn
while using chemicals and handling animals.

•

Gauze (3 in x 3 in), purchased from Tyco Healthcare (Mansfield, MA), were used
to suppress bleeding and clean-up incision sites during animal surgeries.

•

Insulin syringe (1 mL, sterilized), purchased from Becton Dickinson & Co.
(Franklin Lakes, NJ), were used for administration of anesthesia agents during
animal experiments.

•

Membrane filters (47 mm, 0.45 μm, hydrophilic polypropylene, Pall Corp., Ann
Arbor, MI) were used to filter mobile phase for LC-MS/MS analysis.

•

Microcentrifuge tubes (clear), purchased from VWR (West Chester, PA), were
used in sample preparation for microsomal incubations and LC-MS/MS analysis.

•

Nylon 2/0 and 3/0 surgical sutures, purchased from Henry Schein Inc. (Melville,
NY), were used during animal surgery to close incisions and secure the jugular
vein cannula.

•

Pipette tips (10 μL, 20 μL, 250 μL, and 1000 μL), purchased from Ranin
Instrument (Oakland, CA), were used along with the appropriate mechanical
pipettes for volumetric transfer of liquids.

•

Polyethylene tube (I.D. 0.023”, O.D. 0.038”), purchased from Becton Dickson
Intramedic & Co. (Franklin Lakes, NJ), were used for blood sampling via jugular
vein cannula
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•

Powder-free latex examination gloves, purchased from VWR (West Chester, PA),
were worn during all laboratory and animal experiments.

•

Standard silicone tubing (I.D. 0.025”, O.D. 0.047”), purchased from HelixMark
(Carpinteria, CA), were used as the soft front of the polyethylene tubing.

•

Syringe filters (0.45 μm, HPLC certified), purchased from VWR (Radnor, PA),
were used to sterilize anesthesia cocktail.

•

Syringes (1 ml, sterilized, single use), purchased from Becton Dickson &Co.
(Sparks, MD), were used for blood sampling.

3.7.3 Equipment, Apparatus and Software

•

Analyst® software v1.6.2, purchased from SCIEX (Foster City, CA), was used to
control and acquire data from the LC-MS/MS system.

•

Electronic Weighing Balances (AB204-S and AT261 Delta Range), purchased
from Mettler Toledo (Columbus, OH), were used to weigh all solid-state
excipients and drugs.

•

Eppendorf Centrifuge 5427 R (Enfield, CT) was used to centrifuge samples and
working solutions to enable collection of supernatants.

•

Gastight glass syringe, purchased from Hamilton Company (Reno, NV), was used
to tune the mass spectrometer parameters for OJT010 and IS.

•

Sigma Plot v11.0, purchased from Graph Pad Software Inc. (La Jolla, CA), was
used to generate plots and for statistical analysis of data.
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•

LC-MS/MS system consisting of the following was used for the quantification of
OJT010
o 6500+ Triple Quad LC-MS/MS system purchased from SCIEX (Foster
City, CA)
o ABN2ZA Tri Gas Generator purchased from Peak Scientific (Billerica,
MA)
o ExionLC AD UHPLC system (Sciex, Redwood City, CA).
o Kinetex PS C18 column (100 x 2.1 mm, 2.6 µm, 80 Å, Phenomenex Inc.,
Torrance, CA, USA)

•

Phoenix WinNolin® 8.3, purchased from Certara (St. Louis, MO), was used to
estimate pharmacokinetic parameters from rat data.

•

Pipettes, purchased from Rainin Instrument (Oakland, CA) and Eppendorf
(Hamburg, Germany), were used for volumetric measurements.

•

Syringe Pump 11 PLUS, purchased from Harvard Apparatus (Holliston, MA),
was used to tune the mass spectrometer parameters for OJT010 and IS.

•

Vortex machines (Vortex-Genie® 2), purchased from Scientific Industries
(Bohemia, NY), were used mix sample preparations.
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3.7.4 Animals

The animal protocol (ES-IACUC-00) used in this work was reviewed and
approved by the Institutional Animal Care and Use Committee (IACUC) at Texas
Southern University. Additionally, all animal studies were conducted in compliance with
the National Institute of Health “Guide for the Care and Use of Laboratory Animals, 8th
Edition”. Experiments were carried out using adult male Sprague-Dawley rats (body
weight 300 – 350 g) purchased from Envigo RMS, LLC, Alice, TX. Upon arrival, the
animals were housed under normal conditions which includes free access to food and
water, a room temperature environment with 12-hour light-dark cycles from 6 am to 6 pm
daily.

These conditions were maintained for one week before starting animal experiments to
allow for adequate acclimatization of the animal. The animals were implanted with a
cannula tube in the left jugular under anesthesia and allowed to recover for 24 hours
before initiating dosing.
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3.8 Methods for Pharmacokinetic Study

3.8.1 LC-MS/MS Assay Development

A LC-MS/MS analytical method was developed to quantitate the concentrations
of OJT010 in plasma and urine samples collected from pharmacokinetic studies of
OJT010 in rats. The development of the method involved optimizing the massspectrometric settings to get the optimum signal-to-noise ratio, as well as optimizing the
chromatographic conditions to assure the best selectivity and reduce matrix effect caused
by interference in the biological matrix.

3.8.2 Chromatography

The liquid chromatography analysis was performed on the ExionLCTM AD
UHPLC system (Sciex, Redwood City, CA). The chromatographic separation was
achieved using a Kinetex PS C18 column (100 x 2.1 mm, 2.6 µm, 80 Å, Phenomenex Inc.,
Torrance, CA, USA) with a gradient mobile phase at flow rate of 0.4 mL/min. The
sample injection volume was 2 μL, and the mobile phase consisted of a gradient
composition of water (0.5 mM ammonium acetate) (A) and acetonitrile (B). The time
program of the gradient was as follows: Mobile Phase B was initially kept at 20% for 0.2
min, increased from 20% to 70% in the following 2.3 min, then kept at 70% for 1 min,
increased from 70% to 98% in 0.5 min and kept at 98% for 0.5 min, then decreased from
98% to 20% in 0.2 min and kept stably at 40% for 0.8 min. (Table 4)

77
3.8.3 MS/MS Detection

The MS/MS analysis was performed on a 6500+ Triple Quad quadrupole mass
spectrometer system equipped with a Turbo Ion Spray ion source (Sciex, Redwood City,
CA). The hybrid triple quadrupole LIT (linear ion trap) mass spectrometer is equipped
with a Turbo V™ ion source. Pure nitrogen used as curtain gas, and source and exhaust
gases were generated by a Peak Scientific (GENIUS ABN2ZA) Tri Gas Generator.
OJT010-d5 was used as internal standard (IS). The quantification was performed using
multiple-ion reaction monitoring (MRM) in positive mode, with the transitions of m/z
379 → 264 for OJT010 and m/z 384 → 264 for IS. The source parameters were set as
follows: ion spray voltage, 5200 V; ion source temperature, 550°C; nebulizer gas, 70 psi;
heater gas, 70 psi; curtain gas, 45 psi; and the collision gas 11. The compound-dependent
parameters for OJT010 and IS were optimized with entrance potential (EP), 5 V and 5 V;
declustering potential (DP), 60 V and 60 V; collision energy (CE), 27 V and 30 V; and
collision cell exit potential (CXP), 5 V and 5 V, respectively. Analyst® Software 1.6.3
(Redwood City, CA, USA) was used to control the LC-MS/MS system and analyze the
data. the compound dependent electronic parameters for the MS/MS acquisition of
OJT010 and IS are summarized in Table 5.
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Table 1: Electronic Parameters for MS/MS Acquisition of OJT010 and IS

Parent

Transition

Dwell Time

DP (V)

CE (V)

(m/z)

(msec)

OJT010

379 → 264

200

60

27

IS

384→ 264

200

60

30

EP (V)

5
5

CXP (V)

5
5

3.8.4 Standard and Quality Control Samples

The stock solution of OJT010 was prepared by dissolving the solid compound in
100% methanol at a concentration of 1 mg/mL and was stored at −20 °C until it was
used. The IS was prepared by dissolving OJT010-d5 in acetonitrile at the concentration of
1 mg/mL. The OJT010 working solutions were prepared by diluting the stock solution in
100% acetonitrile final concentrations of 10, 5, 1, 0.5, 0.10, 0.05, 0.025, .001, and 0.005
μg/mL. The IS working solution was prepared by diluting the 1 mg/mL stock solution
with 100% acetonitrile to obtain a concentration of 10 ng/mL. A series of standard
samples were prepared by spiking the working solutions (5 μL) into blank rat plasma or
urine (45 μL) to obtain the following concentrations of OJT010: 0.05, 0.1, 2.5, 5, 10, 50,
100, 500, and 1000 ng/mL. The mixture was vortexed for 60 seconds and then
centrifuged at 14,000 rpm for 20 minutes. The resulting supernatant was then transferred
to an auto-sampler vial for LC−MS/MS analysis.
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3.8.5 Plasma and Urine Sample Preparation

Plasma samples stored at −80°C were thawed at room temperature. An aliquot (50
μL) of plasma was extracted for OJT010 using protein precipitation by adding 250 μL of
acetonitrile containing the internal standard (10 ng/mL). The mixture was vortexed for 60
s and centrifuged at 14,000 rpm for 20 min at 4°C. An aliquot of the supernatant was
injected into the LC-MS/MS for quantitative analysis. The lung tissue samples were
prepared by cutting whole lung into small pieces. The lung tissue pieces were weighed.
Then 3 mL of water was added per gram of lung and homogenized using a handheld
homogenizer. Lung samples were processed by taking an aliquot (50 μL) and extracted
using protein precipitation by adding 250 μL of acetonitrile containing the internal
standard (10 ng/mL).

3.9 Pharmacokinetic Studies

3.9.1 General Animal Procedures

Jugular vein cannulation was performed under anesthesia using an aqueous
anesthetic cocktail composed of ketamine: acetopromazine: xylazine (50:3.3:3.3 mg/Kg)
at a dose of 1 mL/Kg the day before the study. A cannula, composed of silicone elastic
tubing (0.02” I.D. and 0.037” O.D.) was inserted into the right jugular vein, secured with
a silk suture tunneled subcutaneously and exteriorized in the dorsal infrascapular area.
The surgical incision was closed with surgical sutures. Cannula patency was maintained
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by flushing the cannula line daily with 0.5 mL of sterile heparinized saline solution (100
units/mL).

3.9.2 Evaluation of Oral Bioavailability

A cross-over design was used in this study to evaluate the oral bioavailability of
OJT010. Adult male SD rats (n=3) weighing 300 – 350 g were cannulated through the
jugular vein under anesthesia one day before the study. Each rat received a 50 mg/kg
intravenous dose of OJT010. Serial blood samples (100 µL each) were collected from
each rat before dose and at 0, 2, 5, 15, 30, 60, 90 minutes, and 2, 3, 4, 6, 10, 24, 28, 32
and 48-hours post dose. After blood centrifugation at 13,000 rpm for 3 minutes, the
plasma supernatants were collected, and immediately stored in -80oC and analyzed within
14 days. We also collected urine samples up to 24 hours post dose and immediately
stored in -800C and analyzed within 14 days. Following a two-week washout period, the
rats were fasted overnight and for four hours after receiving a 250 mg/kg oral dose of
OJT010. Water was always available to the rats. Again, serial blood samples were
collected before dose and at 0, 5, 15, 30, 45, 60, 90 minutes, and 2, 4, 6, 8, 10, and 24hours post dose. Blood samples were centrifuged at 13,000 rpm for 3 minutes, and the
supernatants were collected. Urine samples were collected up to 24 hours after dose.
Urine and plasma samples were stored at -800C and analyzed by LC-MS/MS analysis
within 14 days. Under anesthesia rats were sacrificed and lung was collected at 24 hours
post dose. Lung samples were stored at −80 °C until analysis.
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A multiple dosing design was used in this study to evaluate the oral steady-state
concentrations of OJT010. Adult male SD rats (n=6) weighing 300 – 350 g were
cannulated through the jugular vein under anesthesia one day before the study. Six
Sprague-Dawley rats were randomly distributed into two OJT010 treatment groups; (a)
250 mg/kg and (b) 400 mg/kg. The rats in each group were administered a single oral
dose of 250 mg/kg/day and 400 mg/kg/day, respective, consecutively for five days. Rats
were fasted for at least 12 hour before and 4 hours after the last dose on Day 5. Serial predetermined blood samples were collected at various time points as described in the
previous single dose studies. Urine samples were collected up to 24 hours post dose.
Serial blood samples (100 µL each) were collected from each rat before dose and at 0, 5,
15, 30, 45 minutes, and 1, 1.5, 2, 4, 6, 8,10, 24 hours post last dose. After blood
centrifugation at 13,000 rpm for 3 minutes, the plasma supernatants were collected, and
immediately stored in -80oC and analyzed within 14 days. We also collected urine
samples up to 24 hours post-dose and immediately stored in -800C and analyzed them
within 14 days. LC-MS/MS analysis within 14 days. Under anesthesia rats were
sacrificed and lung was collected at 24 hours post-dose. Lung samples were stored at −80
°C until analysis.

3.9.3 Pharmacokinetic Analysis

Plasma OJT010 concentration versus time data were analyzed for each rat using a
non-compartmental model (WinNonlin 8.1, Pharsight Corp, Mountain View, CA). The
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non-compartmental pharmacokinetic parameters derived after intravenous administration
were maximum plasma concentration (C0), terminal elimination half-life (T1/2), systemic
plasma clearance (Cl), volume of distribution (Vd), the total area under the plasma drug
concentration-time curve from 0 to last sampled point (AUCLast), the total area under the
plasma drug concentration-time curve from 0 to infinity (AUC0-∞), mean residence time
(MRT) as described below in detail:

•

AUCLast – The area under the plasma drug concentration-time curve from time
zero to the last sampling time point was calculated using the trapezoidal
method

•

AUC0-∞ - The area under the concentration-time curve from time zero to
infinity was calculated using the trapezoidal method from the plasma drug
concentration vs time data from time zero to the last experimental time plus
the excess area (from last experimental time to infinity).

•

C0- Estimated initial plasma concentration of drug was determined by back
extrapolation of plasma drug concentration at time 0 following intravenous
drug administration.

•

Cmax- Maximum observed concentration, occurring at Tmax. It is determined by
observation of the plasma- concentration time profile following oral drug
administration.

•

Tmax- Time of maximum observed concentration following oral drug
administration. It is determined by observation of the entire concentration
time- profile.
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•

K - The terminal phase rate constant was determined from the slope of the
terminal linear segment of a semilogarithmic plot of plasma drug
concentration vs. time.

•

T1/2 – The terminal half-life of the drug was calculated as
T1/2 =0.693/K

•

Vd- Volume of distribution was calculated as
Vd= Dose / (K x AUC0-∞)

•

Cl – The total systemic clearance was calculated as
Cl= Dose/AUC0-∞

•

MRT- The mean residence time was calculated using moment analysis
according to the equation
MRT=AUMC0-∞ /AUC0-∞

where AUMC0-∞ is the area under the first moment curve extrapolated to infinity
and AUC0-∞.
•

Vss- The volume of distribution at steady state was calculated according to the
following equation
Vss= Cl x MRT

•

After extravascular administration, the following pharmacokinetic parameters
were calculated using phoenix WinNonlin non-compartmental analysis:

•

F - The absolute oral bioavailability was estimated according to the following
equation:

•

)% =

$+,

/.

$+, //0

1 100%

CHAPTER 4
RESULTS AND DISCUSSION
4.1 Effects of OJT010 and OJT009 on rhACE2 and Spike (RBD) Protein Interaction

The interaction between the human ACE2 and receptor-binding domain of SARSCoV-2 spike protein is a crucial first step in the entry process required for the viral
infectivity (Wrapp et al., 2020). Using an adapted in vitro enzyme-linked immunosorbent
assay (ELISA) (RayBiotech, 2022), we evaluated the effect of OJT010 and OJT009 on
the binding affinity of rhACE2 and RBD of S protein at concentrations ranging from 100
µM to 100 nM. Prism graph pad version 8.4.3 was used to generate dose-response
curves. We observed a unique bell shape curve for both compounds when fitted using a
special bell-shaped curve model. OJT010 was more potent at disrupting the interaction
between ACE2 and RBD than OJT009.
Surprisingly, the percent inhibition was greater at low concentrations of OJT010
than at high values. On the other OJT009, we observed an unexpected bell-shaped curve
with activation and inhibition at opposite ends. OJT009 increased the binding of ACE2
and RBD at high concentrations of 100 and 50 μM but blocked the interaction at low
concentrations.
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For both drugs, the bell-shaped model predicted two IC50 values. The doseresponse curves for OJT009 and OJT010 are shown in Figures 8 and 9. Table 2 displays
the IC50 values for each drug obtained in this assay.

Like our results in the presence of OJT009, Bradfeut al. observed a dosedependent increase in cellular fusion. On the other hand, treatment with 50 µM of
OJT010 resulted in mild inhibition of SARS-CoV-2 activity but did not cause any
enhancement in cellular fusion (SB et al., 2020). Honrich et al. also reported mild
inhibition of SARS-CoV-2 replication with OJT010 (BF et al., 2021).

The findings of our study suggest that OJT010's mechanism action against
SARS-CoV-2 comes from a direct antiviral effect rather than its predicted effects on
TMPRSS2. Even though OJT009 and OJT010 are classed as TMPRSS2 inhibitors,
current research has revealed that these two drugs do not directly block the TMPRSS2
activity (Shrimp et al., 2020). One plausible mechanism for antiviral action of OJT010 in
SARS-CoV-2 could be inhibition of the interaction between ACE2 and the Spike protein,
as reported by our study. More research is needed to understand the role of OJT010 in
SARS-CoV-2.
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Figure 8. Effect of OJT010 and OJT009 on the interaction of rhACE2 and
SARS-CoV-2 Spike (RBD) protein. A. OJT010 and B. OJT009
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Table 2: Effect of OJT010 & OJT009 on the Binding of rhACE2 & RBD of Spike

Estimated Relative IC50 against rhACE2 and RBD Interaction

Assay

Inhibitor ID

IC50_1 (μM)

IC50_2 (μM)

OJT010

0.82

231.6

OJT009

1.19

42.9

4.2 Effects of OJT010 and OJT009 on Exopeptidase Activity of ACE2

To further understand our RBD-ACE2 interaction assay results, we decided to investigate
the role of both drugs on the exopeptidase activity of ACE2. ACE2 exopeptidase activity
is vital for normal physiology, and long-term inhibition of ACE2 could be detrimental to
cardiovascular health (Ni et al., 2020). Therefore, to rule out ACE2 inhibition by our
drugs we determined the effect of OJT010 and OJT009 on the exopeptidase activity of
rhACE2 using an adapted fluorometric assay (BPSBioscience, 2022). We found that
OJT010 doesn’t inhibit the exopeptidase activity of rhACE2 even at a very high
concentration. On the other hand, OJT009 completely inhibited the exopeptidase function
of ACE2 at high concentrations from 50 µM to 500 µM with an IC50 value of 25.98.
Surprising at a low concentration from 0.1nm to 10 µM, OJT009 had no activity against
ACE2. To our knowledge, these results revealed for the first time that OJT010 doesn’t
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inhibit the exopeptidase activity rhACE2, while OJT009 inhibits its function at high and.
Figure 9 shows the dose-response curve for OJT010 and OJT009 against ACE2 activity.

The behavior of OJT009 in the two biochemical assays; ACE2 exopeptidase activity and
rhACE2 and RBD interaction shed light on their mechanism of action. At a high
concentration (above 50µM), OJT009 inhibits the ACE2 activity but enhances the
binding of ACE2 with RBD. While at a low concentration, it does not affect ACE2
activity but disrupts the interaction of ACE2 and RBD. According to these findings
interactions of these compounds with ACE2 modulate the extent of binding between
ACE2 and RBD.

ACE2 has a bound chloride ion in its structure, which plays an essential role in
substrate hydrolysis by ACE2 (Vickers et al., 2002). The presence of chloride and
fluoride ions activate ACE2 and enhances its exopeptidase activity. Furthermore,
chloride ion determines the confirmation of the enzyme in native and inhibitor bound
form (Towler et al., 2004).

OJT010 is known to increase chloride conductance in cystic fibrosis. In our ACE2
exopeptidase assay in the presence of OJT010, we saw an enhancement in the
exopeptidase activity. However, activation of ACE2 by OJT010 was not dose dependent.
More research is needed to prove the results obtained in our study.
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Additional ions play an important role in determining the strength and stability of
RBD and ACE2 binding. It may be possible that OJT010 and OJT009 work by
modulating ions concentrations which cause conformational changes in the structure of
ACE2 and make it less receptive for RBD binding. However, this is just a hypothesis, and
further X-ray crystallography studies are needed to understand the exact mechanism of
action. Nevertheless, our findings reveal a new pharmacologic mode of action and novel
target for OJT010 and OJT009.
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Figure 9: Effect of OJT010 and OJT009 on the Exopeptidase Activity of ACE2.
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4.2 Effects of OJT010 on Exopeptidase Activity of ACE

Earlier in the pandemic, many controversial reports came out concerning the role of ACE
inhibitors (ACEIs) in COVID-19. Many believed that ACEIs will lead to overexpression
of ACE2, which will result in more severe infection. Conversely, observational data from
COVID-19 patients showed better outcomes with ACEIs, leading to speculations that
they will prevent Ang II-mediated pulmonary inflammation and reduce acute lung injury.
To determine if OJT010 interacts with ACE, we examined the role of OJT010 on the
exopeptidase activity of ACE. Like the findings of the ACE2 assay, OJT010 does not
inhibit the activity of ACE. Even in the presence of very high concentrations of OJT010
such as 500 µM, ACE was 100% active.
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Figure 10: Effect of OJT010 on the Exopeptidase Activity of ACE
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4.3 Efficacy of OJT010 against SARS-CoV-2 and Spike (B.1.617.2 Delta Variant) in
a Pseudo virus assay

Based on the behavior of two drugs in the biochemical assays, we decided to move
forward with OJT010 for two reasons. First, it prevents the binding of spike protein with
RBD and doesn’t enhance ACE2 and RBD binding as seen with OJT009. Second, it has
no inhibitory activity against host receptor ACE2.

Therefore, we assessed whether OJT010 can block the infection of cells with spike
Pseudotyped Lentivirus particles. A preliminary screen was done with four
concentrations ranging from10 uM to 100 uM. Interestingly OJT010 effectively blocked
the entry of pseudo spike protein into the cells. We saw a dose-dependent neutralization
of viral particles with increasing concentrations. OJT010 at 50 uM showed a close to
50% reduction of the viral entry (Table 3). This assay further validates the results from
biochemical assays that the interaction of OJT010 with ACE2 and RBD is part of its
mechanism of action for SARS-CoV-2 neutralization.

Next, we evaluated the efficacy of OJT010 to neutralize the B.1.617.2 Delta Variant of
SARS-CoV-2. A similar assay was performed with spike pseudo-type lentiviral particlecontaining B.1.617.2 Delta Variant gene. Interestingly at the concentrations tested,
OJT010 retained similar potency as of wild type SARS-CoV-2. OJT010 blocked the
entry of viral particles by 50% at 50 uM and 100% at 100 uM. Surprising, OJT010 was
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slightly more potent against the delta variant of SARS-CoV-2 than the wild-type virus
(Table 3).
Given that Pseudotyped assay only measures the effect of the compound on
preventing the entry of spike protein into the cells, it further substantiates our hypothesis
that OJT010 interacts with the entry receptors. Further studies are needed to identify the
actual target of OJT010 in the SARS-CoV-2 inhibition pathway. To our knowledge, this
is the first study revealing a new mechanism of action for OJT010 in regards to ACE2RBD interaction in SARS-CoV-2 pathogenesis.

Table 3: Effect of OJT010 on the SARS-CoV-2 and Delta Variant Pseudo typed
Lentivirus Infection in ACE2 HEK-293 cells

Percent (%) Inhibition of Pseudo virus Entry in HEK293 Kidney Cells
Percent Inhibition

SARS-CoV-2

B.1.617.2 Delta Variant

Conc (μM)

OJT010

OJT010

100

89

95

50

46

48

25

12

19

10

2

6
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4.4 Efficacy of OJT010 against SARS-CoV-2 Infection-Induced Cytopathic Effect
(CPE) in Vero E6 cells

To determine whether the results obtained in biochemical, and Pseudo typed assay also
apply to SARS-CoV-2 infection in vitro. We evaluated the antiviral activity of OJT010
using a standard luminescent-based high-throughput screening (HTS) platform for SARSCoV-2 infection-induced CPE in African Green Monkey Kidney Vero E6 cells (CB et al.,
2008; WE et al., 2007). As expected, the treatment with OJT010 inhibited SARS-CoV-2
infection-induced CPE in vitro with a 50% Inhibitory Concentration (IC50) value at about
~150 μM. The IC50 obtained in this assay is almost two-fold higher than the IC50 in the
Pseudtyped assay. One reason for the variability in IC50 values is the use of different cell
lines. In the Pseudo virus assay, we used HEK293 kidney cells, While VeroE6 cells were
used in the CPE assay. Moreover, Pseudotyped lentiviral assay only measures the entry
of the spike particles into the cell. It doesn’t quantify viral replication and other viral
factors essential in the SARS-CoV-2 infection pathway. Even though VeroE6 cells are
often used for SARS-CoV-2 infection and propagation, they were originally obtained
from the African green monkey kidney and hence did not represent an ideal model for
SARS-CoV-2 infection because it targets mainly the respiratory cells from the human
lung. Moreover, the CPE assay is an indirect measure for viral replication by determining
cell viability after the infection.

In addition to OJT010, we evaluated the antiviral activity of four known inhibitors
SARS-CoV-2 as positive controls for the current assay: Calpain Inhibitor IV,
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Chloroquine, Remdesivir, and Aloxistatin. The IC50 values for most of the reference
compounds (Calpain Inhibitor IV (3.73 μM), Chloroquine (8.85 μM), and Remdesivir (16
μM)) and Aloxistatin (4.58 μM) were significantly lower than the IC50 values for
OJT010. The IC50 values for the reference substances obtained in our assay were like
previously reported IC50 (Chen et al., 2020; OA et al., 2021; M. Wang et al., 2020).
Figure 10 shows the dose-response curve for OJT010 and reference compounds against
SARS-CoV-2 infection-induced cytopathic effect. Table 4 shows the structure and
effective concentration for the reference compounds.
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Figure 11: Efficacy of Reference Inhibitors against SARS-CoV-2 Induced
Cytopathic Effect (CPE) in Vero E6 cells: A Calpain Inhibitor IV, B, Chloroquine,
C.E64d (Aloxistatin), D. Remdesivir.
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Table 4: Activity of OJT010 and Reference Compounds against SARS-CoV-2
Induced Cytopathic Effect in Vero E6 Cells

Inhibitor ID
OJT010

IC 50 (μM)

Maximum Inhibition (%)

Concentration at Maximum % Inhibition (μM)

>150

49.87

150

3.73

115.91

7.17

4.59

130.81

15

8.85

114.51

30

16.07

120.89

30

CalpainInhibitorIV

E64d (Aloxistatin)

Chloroquine

Remdesivir
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4.5 Cytotoxicity Effects of OJT010 in Vero E6 cells

We measured the cytotoxicity of OJT010 and reference compounds using a Cell
Titer-Glo Luminescent Cell Viability Assay (WE et al., 2007) in Vero E6 cells and
observed the 50% cytotoxic concentration (CC50) of OJT010 was 183.71μM. At the
concentration of 300 μM, the percent viability was 0.55%, while maximum viability of
96 % was seen at a low concentration of 0.59 μM. The CC50 values were also obtained
for the reference compounds. For reference compounds, the maximum tested
concentration was 30 μM. Figure 11 shows the cytotoxicity of OJT010 in VeroE6 cells,
and Table 5 represents the cytotoxicity and percent viability of cells for OJT010 and
reference compounds.
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Figure 12: Cytotoxicity of OJT010 in VeroE6 cells
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Table 5: Cytotoxicity of OJT010 in Vero E6 Cells, in Comparison to Reference
Inhibitors of SARS-CoV-2

Inhibitor ID

Cytotoxicity
CC50 (μM)

Minimum
Viability
(%)

Concentration
at Minimum %
Viability (μM)

Maximum
Viability
(%)

Concentration at
Maximum %
Viability (μM)

OJT010

183.71

0.55

300

96.64

0.59

CalpainInhibitorIV

>7.17

99.77

0.028

106.84

0.056

E64d (Aloxistatin)

>30.00

93.02

0.117

106.71

0.234

Chloroquine

>30.00

90.50

3.750

99.66

0.469

Remdesivir

>30.00

91.15

0.117

100.73

3.750
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4.6 Effect of OJT010 on the Replication of SARS-CoV-2 Nanoluciferase Reporter
Virus Assay 549 cells

After determining the IC50 in CPE, we measured the potency of OJT010 in inhibiting the
viral replication in A549 cells using Nanoluciferase Reporter Virus Assay (NLRV). A549
cells are human epithelial lung cells that are optimized to express AEC2. Unlike CPE,
Nanoluciferase assay is a direct measure of viral replication, and efficacies were
evaluated by quantifying the viral level in the cells. Moreover, CPE assay is done veroE6;
in contrast, NLRV is done A549 lung cell line, representing a closer model for SARSCoV-2 infection in vivo.

In the NLRV assay, the EC50 of OJT010 is 47 μM compared to 150 μM in the CPE assay.
The EC50 obtained by the NLRV assay is very close to what we have seen in the
Pseudotyped lentiviral assay. In addition to OJT010, we also evaluated the antiviral
activity of other inhibitors SARS-CoV-2 as positive controls for the current assay:
Calpain Inhibitor IV, Chloroquine, Remdesivir, Paxlovid, and Molnupiravir. Similar to
OJT010, reference compounds were also more potent in this assay compared to the CPE
assay. The IC50 values for most of the reference compounds (Calpain Inhibitor IV (.0005
μM), Chloroquine (3.3 μM), and Remdesivir (3.3 μM), Paxlovid (0.05 μM), and
Molnupirvair (4.2 μM) were significantly lower than the IC50 values for OJT010. Figure
12, and 13 shows the dose-response curve for OJT010 and reference compounds against
SARS-CoV-2 replication Nanoluciferase Reporter Virus Assay 549 cells. Table 6 shows
the IC50 value of OJTO10 in comparison to reference compounds.
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Figure 13: Efficacy of OJT010 against SARS-CoV-2 in Nanoluciferase
Reporter Assay in A549 cells
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Figure 14: Efficacy of Reference Inhibitors against SARS-CoV-2
NLRV in Vero E6 cells: A CalpainInhibitorIV, B, Chloroquine, C.
Remdesivir, D. Paxlovid, E. Molnupiravir
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Table 6: Activity of OJT010 and Reference Compounds against SARS-CoV-2
infection using NLRV assay in A549 lung cells

IC 50

Maximum

Concentration at Maximum %

(μM)

Inhibition (%)

Inhibition (μM)

OJT010

47.33

99.73

300

CalpainInhibitorIV

0.0005

99.56

.0028

PF-07321332

0.057

99.67

0.5

Chloroquine

3.3

99.53

15

Remdesivir

0.336

99.58

1.5

Molnupiravir

4.2

91.12

10

Inhibitor ID
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4.7 Cytotoxicity of OJT010 in A549 lung Cells using NLRV Assay

We also obtained the CC50 for OJT010 and reference compounds in A549 cells.
The cytotoxic concentration obtained in this assay was 137.18 μM a little less than the
CPE assay. However, it was still very high compared to the reference compounds. At 300
μM, only 0.14% of cells were viable. Cytotoxicity for OJT010 and reference compounds
are shown in Table 6. Figure 14 shows a graph for CC50 of OJT010 in A549 cells
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Figure 15: Cytotoxicity of OJT010 in A549 Lung Cells
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Table 7: Cytotoxicity of OJT010 in A549 Cells, in comparison, to Reference
Inhibitors of SARS-CoV-2

Inhibitor ID

OJT010

Cytotoxicity
CC50 (μM)

137.44

CalpainInhibitorIV >0.179

Minimum
Viability
(%)

Concentration
at Minimum
% Viability
(μM)

Maximum
Viability
(%)

Concentration
at Maximum%
Viability (μM)

0.14

300

100

2.34

77.49

.0056

94.37

.090

Chloroquine

18.37

9.11

30

117.48

.023

Remdesivir

>3

84.65

0.094

95.46

.006

Paxlovid

>1

89.51

0.004

101.24

1

Molnupiravir

>10

88.88

0.014

98.56

.002
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4.8 Efficacy of OJT010 against B.1.617.2 Delta Variant Infection-Induced
Cytopathic Effect (CPE)

To validate the preliminary results of the Pseudotyped delta virus assay, we assessed the
efficacy of OJT010 in inhibiting delta viral replication in CPE assay. A luminescentbased high-throughput screening (HTS) platform was used to evaluate the antiviral
activity of OJT010 against delta variant of SARS-CoV-2 infection-induced CPE in
African Green Monkey Kidney Vero E6 cells. We found that OJT010 inhibited B.1.617.2
Delta Variant infection-induced CPE in vitro with a 50% Inhibitory Concentration (IC50)
value at about 98 μM. The results were similar to what we saw earlier in the Pseudotyped
assay. OJT010 is more potent against B.1.617.2 Delta Variant than wild typed SARSCoV-2. In addition, to OJT010, we also tested the antiviral activities of known SARSCoV-2 inhibitors as reference compounds: The IC50 values for the majority of the
reference compounds (Calpain Inhibitor IV (0.124 μM), Chloroquine (8.3 μM), PF07321332+EI (0.029 μM) , Remdesivir+Pfz EI (0.17 μM), PF-07321332 (1.98 μM),
E64d (Aloxistatin) (9.84 μM)and Remdesivir (8.24 μM) were lower than the IC50 values
for OJT010. Figure 15 and 16 shows the IC50 dose-response curve for OJT010 and
reference compounds respectively. Table 8 shows the efficacy of OJT010 in comparison
to reference compounds.
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Figure 16: Efficacy of OJT010 against Delta Variant of SARS-CoV-2 in Infection
Induced Cytopathic Effect (CPE) assay
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Figure 17: Efficacy of Reference Inhibitors against Delta SARS-CoV-2 CPE in Vero
E6 cells: A CalpainInhibitorIV, B, PF-07321332, C. Chloroquine, D.
Remdesivir+Pfz EI, E. Remdesivir, F E64d (Aloxistatin), G PF-07321332+EI
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Table 8: Activity of OJT010 and Reference Compounds against Delta Variant of
SARS-CoV-2 in CPE assay

Inhibitor ID

OJT010

IC
(μM)

Maximum
Inhibition (%)

Concentration at Maximum %
Inhibition (μM)

98.23

88.38

150

0.124

105.43

0.45

1.98

96.28

10

8.3

993.48

15

8.24

104.26

15

0.029

116.90

.08

0.170

88.29

.47

9.82

85.17

15

50

CalpainInhibitorIV

PF-07321332

Chloroquine
Remdesivir
PF-07321332 + EI
Remdesivir + Pfz EI
E64d (Aloxistatin)
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4.9 Effect of Combination of Remdesivir and OJT010 on the Replication of SRASCoV-2 in NLRV assay

We determine the effect of the combination of OJT010 and Remdesivir on SARSCoV-2 replication at the same concentration as monotherapy. We used the Zero
interaction potency (ZIP) model to characterize the interactions between the two drugs.
This model evaluates drug response by comparing drug response curves between
individual drugs and their combination. A synergy score obtained in this assay ranges
from -10 to 10. It can be interpreted as an average increase in drug response due to drug
interaction. For example, a synergy score of 10 corresponds to a 10% response beyond
expectations. Based on the score obtained, drugs are classified as antagonist, additive and
synergistic. Three major score windows; (A) Score of (-10) represent antagonistic
behaviour, (b) Scores between -10 to 10 are likely due to being an additive effect of drugs
on each other, while (3) Scores greater than 10 represents synergism between the tw0
compounds.

In our study, we obtained a combined score of 0.37. This means that drugs are
showing an additive effect on each other. We observed an additive effect of remdesivir
on OJT010. Increasing concentrations of remdesivir (0-.2 µM) potentiated the effect of
OJT010 seen at 37.5 and 75 µM. Remdesivir alone at these concentrations (0 to 0.2 µM)
had no activity of its own against SARS-CoV-2.
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Interestingly addition of OJT010 decreases the potency of remdesivir. At 0.4 µM,
remdesivir had a percent inhibition of 94, but when increasing concentrations of OJT010
are added, there is a drop in the percent inhibition by remdesivir. The paradoxical
behavior of OJT010 couldn’t be explained based on the finding of this assay. Further
studies are needed to understand the unique relationship between these drugs.

Figure 18: Effect of Combination of OJT010 and Remdesivir on SARS-CoV-2
Replication in NLRV assay
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4.10 Inhibitory Mechanism of OJT010 as Potent Blockers of Molecular Interaction
between SARS-CoV-2 Spike protein and Human Angiotensin-converting Enzyme-2

We used computational tools to investigate the inhibitory potentials of OJT010 as potent
blockers of the molecular interactions between the ACE2 and RBD of SARS-CoV-2 and
Delta Variant. We examined how the binding of OJT010 at the RBD site of the spike
protein and the exopeptidase site of hACE-2 affected the binding affinity and molecular
interactions between RBD and ACE2 Complex. The binding energies (Gbind) between
the two proteins were calculated using the molecular mechanics/generalised born surface
area (MMGBSA) computational approach. Table 1.0 shows the binding affinity of the
two proteins before and after the medicines bind to the Spike protein's RBD site.

First, we identified the binding energies for the ACE2 and RDB complex and then
evaluated the change in binding energy after OJT010 binds to the RBD of the spike
protein. The results showed high binding energy of -64.856 Kcal/mol for ACE2 and RBD
complex in the absence of any drugs (unbound complex). We saw no significant
difference in the binding energy of the ACE2 and RBD complex after docking OJT010
on the RBD site.
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Table 1 shows the binding affinity of ACE2 and RBD complex alone (-64.856 Kcal/mol)
and in OJT010 bound state (-62.442 Kcal/mol). This indicates that the binding of OJT010
to the spike RBD does not affect the complex’s binding affinity or molecular interaction.

Further analysis of the binding energies of OJT010 at the RBD site of spike protein
revealed that it has comparatively modest binding energies at the RBD site of spike
protein (Table 2). This explains why OJT010 had such a small impact on the binding
affinities of the complex.

Next, we examined the impacts of the binding of OJT010 at the exopeptidase site of
hACE-2 on the binding affinity and molecular interactions between ACE2 and RBD
complex for wild type and Delta variant SARS-CoV-2. The binding of OJT010 at the
exopeptidase site significantly reduced the binding energies for the complex (Table 3). A
decrease in binding affinity was more significant with Delta variant compared to the wild
type. These findings imply that the binding of OJT010 to the exopeptidase site of hACE2 reduces the binding affinity for the formation of ACE2 and RBD complex.

These promising results prompted further analysis into the binding energies of OJT010 at
the hACE-2 exopeptidase site (Table 4.0). The results revealed that OJT010 has greater
binding energies at the hACE-2 exopeptidase site than at the RBD site. Taken together
with findings of our study show that the binding of OJT010 at the exopeptidase site of
hACE-2 lowers the binding affinity for the formation of ACE2 and RBD complex.
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Table 9: Thermodynamic Binding Free Energy Profiles for the Spike RBD towards
hACE2 before and after ligands binding at RBD-hACE2

Energy Components (kcal/mol)

Complex

Δ EvdW

ΔEelec

ΔGgas

ΔGsolv

ΔGbind

Spike RBD

hACE-2

-97.11 ± 7.20

-633.80 ± 32.28

-730.92 ± 33.67

666.06 ± 30.00

-64.85 ± 10.19

hACE-2 (OJT010)

-101.18 ± 6.2

-640.13 ± 37.29

-741.32 ± 37.29

676.88 ± 36.20

-62.44 ± 8.08

ΔEele electrostatic energy, ΔEvdW van der Waals energy, ΔGbind total binding free energy, ΔGsol solvation free
energy, ΔEgas gas-phase free energy

Table 10: Thermodynamic Binding Free Energy Profiles for the ligands at the
hACE2-Spike RBD site

Energy Components (kcal/mol)
Complex Δ EvdW

ΔEelec

ΔGgas

ΔGsolv

ΔGbind

-198.96 ± 15.77

-211.81 ±

198.13 ±

-24.68 ±

17.35

17.35

4.66

Spike RBD
OJT010

-18.85 ± 3.78

ΔEele electrostatic energy, ΔEvdW van der Waals energy, ΔGbind total binding free energy, ΔGsol solvation free
energy, ΔEgas gas-phase free energy
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TABLE 11: Results of Binding Energies and Interactions Between ACE2 And
SARS-CoV-2 Spike `Before and After Drugs Bind to Exopeptidase Site Of ACE2
Unbound

OJT010

WT

DT

WT

DT

Binding Energy/Affinity

-211.5±23.8

-50.6±6.8

-137.8±21.8

-23.7±3.9

DOCK score

-119.8±0.2

-59.2±6.5

-116.6±3.8

-59.5±6.1

Z-Score

-1.6

-1.4

-1.6

-1.7

KEY: WT-WILD TYPE, DT-DELTA TYPE

Table 12: Thermodynamic Binding Free Energy Profiles for the ligands at the
hACE2 binding site of hACE2-Spike RBD

Energy Components (kcal/mol)

Complex

Δ EvdW

ΔEelec

ΔGgas

ΔGsolv

ΔGbind

177.787±7.899

-42.231±5.324

Spike RBD

OJT010

-31.797±7.254

-195.455±6.282

-214.784±19.098

ΔEele electrostatic energy, ΔEvdW van der Waals energy, ΔGbind total binding free energy, ΔGsol solvation free
energy, ΔEgas gas-phase free energy
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4.11 Single Dose Pharmacokinetic Studies Evaluating Oral Bioavailability

We conducted a preliminary study in a rat given 100 mg/kg intravenous bolus
administration. After dose, the rat was lethargic but survived; therefore, the
amount was reduced by half for future studies. No animal distress was observed at
50 mg/kg, IV bolus dose or at 250 mg/kg oral dose.

Figure 19 shows the mean plasma concentration-time profiles of OJT010 after a
50 mg/kg IV bolus administration to rats. The data showed a tri-exponential
profile where OJT010 plasma concentrations decreased rapidly immediately after
IV administration, followed by a slower decrease, and further slowed at later
points.

Following oral administration, Pharmacokinetic Parameters and Oral
Bioavailability of OJT010 after Single Oral Dose Study are summarized in Table
13.

OJT010 has a mean terminal elimination half-life was 7.9 Hours. There was < 1%
of unchanged OJT010 excreted in the urine by 24 hours post dose. Following the
oral 250 mg/kg administration, OJT010 was absorbed rapidly reaching a mean
maximum plasma concentration (Cmax) of 2,560 ng/mL in 30 mins. OJT010 was
well absorbed, with absolute oral bioavailability of 15 ± 5.8 %. Interestingly, after
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an oral dose, the mean concentration of OJT010 in the lungs was 317 ng/g at 24 h
post-dose, whereas there was only about 20 ng/mL of the drug concentration in
plasma at 24 h post-dose. Figure 20 shows the mean plasma concentration-time
profiles of OJT010 after a 250 mg/kg oral dose to rats.

Table 13: Pharmacokinetic Parameters and Oral Bioavailability of OJT010
PK Parameters
Units
IV (n=3)
mg/kg
50
hr
ng/mL
19326 ± 3931
hr*ng/ml
8809 ± 715
mL/kg
61591 ± 41096
ml/hr/kg
5697 ± 478
hr
7.2 ± 4.2
%

Route of Administration
Dose
Tmax
Cmax
AUC last
V/F
Cl/F
T1/2
F
Average % dose excreted in
urine in 24 hours
%
after Single Oral Dose Study

0.32 ± 0.11

P.O. (n=3)
250
0.5 - 0.75
2560 ± 709
6678 ± 1901
452901 ± 228004
37752 ± 9097
7.9 ± 2.4
15.5 ± 5.8
0.13 ± 0.3

Cmax = maximum plasma concentration; AUC last = area under the curve from
time 0 to the last dose measured; V/F = apparent volume of distribution; CL/F =
apparent systemic clearance; = T1/2 elimination half-life; CL = total clearance; Vd
= apparent volume of distribution; F = absolute oral bioavailability
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Figure 19: Mean Plasma Concentration-Time Profile of OJT010 following
Single IV (50 mg/kg) Dose in Rats
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Figure 20: Mean Plasma Concentration-Time Profile of OJT010 following
Single oral (250 mg/kg) Dose in Rats
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Multiple-dose Pharmacokinetic Study

Six Sprague-Dawley rats were randomly distributed into two OJT010 treatment
groups; (a) 250 mg/kg and (b) 400 mg/kg. The rats in each group were
administered a single oral dose of 250 mg/kg/day and 400 mg/kg/day, respective,
consecutively for five days. Rats were fasted for at least 12 hour before and 4
hours after the last dose on Day 5. Serial pre-determined blood samples were
collected at various time points as described in the previous single dose studies.
Urine samples were collected up to 24 hours post dose. Table 2 summarizes
mean plasma concentrations observed after multiple doses.

Two-compartmental analyses were used to generate PK parameters for OJT010.
Table 3 shows PK parameters after multiple dosing for two-compartmental
analysis. Following oral administration, Pharmacokinetic Parameters and Oral
Bioavailability of OJT010 after Multiple Oral Dosing Study are summarized in
Table 14.

OJT010 has a mean terminal elimination half-life was 10 and 62 hours with 250
mg/kg and 400 mg/kg respectively. There was < 1% of unchanged OJT010
excreted in the urine by 24 hours post dose. Following the oral of 250 mg/kg and
400mg/kg administration, OJT010 was absorbed rapidly reaching a mean
maximum plasma concentration (Cmax) of 826 ng/mL and 1117 ng/ml in 43 and
20 mins respectively. Interestingly, after an oral dose, the mean concentration of
OJT010 in the lungs was 20~22-fold higher than in the plasma at 24 h post-dose.
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Figure 21 shows the mean plasma concentration-time profiles of OJT010 after a
250 mg/kg and 400 mg/kg oral dose to rats.

The area under the curve for the group was 3354.90 hr*ng/ml and 4812.46
hr*ng/ml with 250mg/kg and 400mg/kg respectively. Table 15 shows the Plasma
Concentrations of OJT010 following Oral Administration of Single and Multiple
Dose in Rats

Following both single and multiple-dose administration, OJT010 concentrationtime profiles were characterized by a rapid absorption phase, with peak plasma
concentrations occurring in less than 1 h for all groups. The Cmax and AUC0-∞
obtained in the multiple-dose study were lower than the single-dose study. The
T1/2 of multiple-dose with 400 mg/kg dose was significantly higher (60 h) than the
single-dose group (12 h).

To study the difference obtained between the PK parameters of multiple-dose and
single-dose group we conducted the analysis of variance (ANOVA). Scores
obtained showed significant variance in the values of Cmax/Dose with a p-value of
0.02. A post hoc Tukey test showed that single-dose study vs multi-dose study at
400mg/kg differed significantly with a p-value of 0.03. Although all parameters
were lower with multiple dosing compared to the single dosing study, none except
dose-normalized Cmax were statistically significant. The discrepancies in Cmax
could be attributed to a small number of animals used in our study. More studies
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with a higher number of animals are needed to rule out obtained differences in our
study.

Table 14: Pharmacokinetic Parameters and Oral Bioavailability of OJT010 after
Multiple Oral Dose Study
PK Parameters
Route of Administration
Dose
Cmax
T1//2ka
T1/2
AUC0-∞
Cl_F
V2_F
V1_F

Units
mg/kg
ng/mL
hr
hr
hr*ng/ml
L/hr/kg
L/Kg
L/kg

Oral (n=3)
250 mg/kg
826 ± 233
0.34 ± 0.33
10 ± 3.8
3844 ± 811
66 ± 12
2006 ± 2939
215 ± 138

Oral (n=3)
400 mg/kg
1117 + 465
0.13 ± 0.14
62 ± 46
7371 ± 3392
66 ± 40
2174 ± 1415
296 ± 133

Tmax
Average % dose excreted
in urine in 24 hours

hr
%

0.72 ± 0.31
0.53 ± 0.05

0.49 ± 0.33
0.40 ±.07

Cmax = maximum plasma concentration; AUC0-∞= area under the curve from time 0 to the infinity;
Vz_pred = volume of distribution; Cl_F = apparent systemic clearance; T1/2 = elimination half-life; CL =
total clearance; V2_F = apparent volume of distribution; F = absolute oral bioavailability
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Table 15: Plasma Concentrations of OJT010 following Oral Administration of
Single and Multiple Dose in Rats

Rat #
Drug
Loading
solution Conc
(mg/mL)
Dosage
(mg/kg)
Route

D2

E2

F2

G

20

20

20

35

250

250

250

250

P. O

P. O

P. O

P. O
P. O
P. O
Multiple dose (5 days,
once daily)

Single dose
Day 1
weight(g)
Day 1 dosing
volume (ml)
Day 2 weight
(g)
Day 2 Dosing
volume (ml)
Day 3
weight(g)
Day 3 Dosing
volume (ml)
Day 4
weight(g)
Day 4 Dosing
volume (ml)
Day 5 weight
(post
overnightfasting) (g)
Day 5 Dosing
volume (ml)
0*
5min
15min
30min
45min
1h
1.5h
2h
4h
6h
8h
10h
24h
Ratio of
Clung/Cplasma
(Ave.=17.7)
Conc. in Lung
at 24h

H
OJT010

I

J

K

L

35

35

35

35

35

250

250

400

400

400

P. O
P. O
P. O
Multiple dose (5 days, once
daily)

306

321

260

287

290

299

301

325

302

3.8

4.0

3.2

2.05

2.07

2.14

3.44

3.71

3.45

297

307

315

303

324

310

2.12

2.19

2.25

3.46

3.7

3.54

301

309

317

315

323

309

2.15

2.21

2.26

3.6

3.69

3.53

299

312

317

317

320

314

2.14

2.23

2.26

3.62

3.66

3.59

287

294

297

297

300

297

2.0

2.0

2.0

3.4

3.4

3.4

<0.5
368
820
1830
2050
1520
1295
1030
358
178
71.8
40.1
18.4

<0.5
775
2260
2100
1515
1155
1020
945
531
190
65.3
126
25.7

<0.5
2225
3370
3000
2010
2340
1835
1285
581
124
100
347
15.9

104
108
581
889
902
1010
854
866
232
59.9
65.4
20.4
4.9

76.8
99.7
476
547
561
401
328
462
229
48
36.5
28.2
19.7

82.5
221
868
1170
875
802
634
469
244
85.6
58.4
41.5
26

48.9
181
1570
1700
2220
1460
1020
1210
951
226
115
66.3
26

82.1
397
712
548
544
356
352
244
251
102
286
86.1
42.6

80.2
1110
1120
847
752
516
414
276
201
79.4
66.8
55
55.6

9

18.2

20

24

24.6

14.1

7.6

19.2

22.2

165.6

468

317.6

117.6

484

366.2

197.8

816

1232
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(ng/g)
Mean + SD
(ng/g)
Lung weight
(g)
Total amount
in lung (ng)
Concentration
in urine
(ng/mL)
Urine volume
(mL)
Total amount
in urine (µg)

317 + 151

323 + 187

749 + 520

1.6298

1.7356

1.0885

1.3143

1.2373

1.2168

1.2476

1.3916

1.2074

269.89

812.26

345.71

154.56

598.85

445.59

246.78

1135.55

1487.52

4540

11700

6810

26100

35600

32850

22300

72600

48400

17.5

9

15

13

11

13

18

7

12

79.5

105.3

102.2

339.3

391.6

427.05

401.4

508.2

580.8
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Figure 21: Mean Plasma Concentration-Time Profile of OJT010 following
Multiple Oral (2500 and 400 mg/kg) dosing in Rats

CHAPTER 5
SUMMARY AND CONCLUSION

The ongoing pandemic of coronavirus disease (COVID-19) caused by the highly
infectious pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
presents a global public health challenge. To contain the pandemic, successful
intervention strategies are urgently needed. Effective therapeutic countermeasures against
SARS-CoV-2 infection require inhibition of critical viral entry and post-entry pathways
targeting viral enzymes or host receptors. The advent of SARS-CoV-2 variants with
mutations in the viral genes has made it imperative to discover therapeutics that target the
host receptors for COVID-19 treatment. Therefore, our research has focused on targeting
the two critical host entry receptor: Angiotensin-converting enzyme-2 for SARS-CoV-2
entry into the human cells.

Small molecule antivirals can inhibit viruses through multiple mechanisms,
including preventing viral entry, inhibiting viral and host proteases, inducing or inhibiting
autophagy, decreasing inflammatory markers, and improving lung conditions. Several
drugs are under evaluation in clinical trials to treat COVID 19.
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Through targeted drug discovery efforts for repurposing existing clinically
approved drugs for the potential treatment of SARS-CoV-2, here we report the potent
antiviral activity of OJT010 against SARS-CoV-2 in human lung epithelial and African
green monkey kidney cells. Here we report that OJT010 inhibited SARS-CoV-2 and
Delta variant and improved viability of VeroE6 kidney cells. Furthermore, it inhibited
viral replication in Nano luciferase reporter assay at micromolar concentrations.
Additionally, it also prevented the entry of Pseudotyped spike particles into VeroE6 cells.

Our study noted that EC50 values of OJT010 were high against SARS-CoV-2.
However, clinical concentrations approaching 100 µM are safe in long-term use in
Parkinson’s disease, Gaucher disease, and pregnant women (H et al., 2022; M & B, 2008;
Magalhaes et al., 2018; S et al., 2020; Y et al., 2022). Furthermore, OJT010 at high doses
has been demonstrated to reduce inflammatory cytokines (TNF-a and IL-1, IL-6, Nf-kB)
(D et al., 1994; KM et al., 2008). Additionally, at high doses, OJT010 improves
oxygenation (PaO2/FiO2 ratio, Po2, and SaO2) while lowering inflammatory markers in
Acute respiratory distress patients, which would be highly desirable in COVID 19
patients (D et al., 1994).

We also investigated the ability of OJT010 and its progenitor drug OJT009 to
modulate the critical interaction between the RBD of SARS-CoV-2 spike protein and
human ACE2. Here we show that OJT010 inhibits the interaction of SARS-CoV-2 spike
protein receptor-binding domain (RBD) with human recombinant ACE2 (rhACE2) in
nano to the micromolar range, thereby blocking its entry into human cells.
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In this study, we explored the possibility of OJT010 and OJT009 as potential
effectors of exopeptidase activity of ACE2. Using a fluorogenic assay, we found that
OJT010 has no effects on the exopeptidase activity of ACE2, while OJT009 inhibits the
exopeptidase activity of ACE2 at high concentrations. ACE2, a membrane-bound
metalloprotease and an essential component in the Renin-Angiotensin system converting
Angiotensin II (Ang II) to Angiotensin 1-7, a potent vasopressor. Although ACE2
facilitates viral entry, it protects against acute lung damage, implying that the ACE2/Ang
1-7 pathway must be carefully manipulated to reduce SARS-CoV-2 induced lung
injuries. ACE2 counteracts ACE negative effects in the lungs by decreasing Ang II
levels. Downregulation of ACE2 by SARS-CoV-2 creates an imbalance of ACE2 and
ACE in the lungs. This further aggravates lung inflammation by increasing capillary
permeability and leading to pulmonary edema. This further activates the releases of
inflammatory markers, which eventually lead to cytokines storm (D. P et al., 2020).

To further investigate the mechanism of action of OJT010 in SARS-CoV-2
inhibition, we used artificial intelligence to evaluate the binding parameters of OJT010
with RBD of Spike protein and ACE2. Using molecular docking techniques, we also
assessed the effect of OJT010 on the molecular interaction between RBD and ACE2. We
discovered that the binding of the OJT010 at the RBD-ACE-2 site does not alter the
binding affinity and molecular interaction between RBD and ACE2. Whereases the
binding of OJT010 at the exopeptidase site of ACE2 considerably lowered the binding
affinities between the proteins compared to the unbound, ACE2-RBD complex. The
result further showed that OJT010 has a good affinity at the exopeptidase site of ACE2.
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Interestingly the binding energies of the Delta variant with ACE2 were greater than wild
type SARS-CoV-2, and hence more significant disruption of the complex was obtained.
These findings validate the in vitro efficacies of OJT010 obtained in CPE, NLRV, and
Pseudo virus assay.

Our study shows multiple lines of evidence that OJT010 mediated inhibition of
SARS-CoV-2 entry through its interactions with ACE2. Our findings suggest that
OJT010 binding to rhACE2 may preserve its physiological function and will prevent nontarget cardiac toxicities observed in other ACE2 modulating drugs. To our knowledge,
this is the first experimental study revealing this class of compounds as potent effectors
of ACE2 exopeptidase activity. This study provides strong evidence that OJT010 could
serve as a promising lead for developing SARS-CoV-2 inhibitors and potential COVID19 therapeutics.

In addition to the anti-SARS-CoV-2 activity of OJT010, it protects against
infections in multiple ways. As discussed earlier, OJT010 is a potent anti-inflammatory
and antioxidant agent. It provides a defense against acute and chronic respiratory diseases
(KM et al., 2008). Moreover, it has been shown that administration of OJT010 could
significantly lessen the extent of ventilation induce lung injury in rats (DW et al., 2019).
Furthermore, it increases lung levels of other antibiotics and potentiates their different
antibiotics activity (V & GS, 2019).
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Additionally, OJT010 has shown efficacy against SARS-CoV-2, rhinovirus, and
influenza virus in cells. In animal models of rhinovirus infection, OJT010 effectively
improved the survival rate of mice by suppressing virus multiplication (C et al., 2020; M
et al., 2014). It has a wide range of actions with minimum adverse events and a favorable
safety profile (M & B, 2008). These unique characteristics indicate that OJT010 could be
a novel therapeutic agent for treating SARS-CoV-2.

To guide the design of efficacy studies in a hamster model of SARS-CoV-2
infection and further develop for Phase I/Phase II clinical trials, we investigated
pharmacokinetics parameters of OJT010 in healthy rats. In the study, we determined the
oral bioavailability of OJT010 and obtained steady-state concentration. In rats’ oral
bioavailability of OJT010 was~15%. The maximum plasma drug concentration (2560
ng/ml) following a single oral dose of 250 mg/kg reached between 30-45 minutes. High
penetration of OJT010 was observed in the lungs ranging from 15~20 fold higher than
plasma. High drug concentrations were highly safe, and adverse events were reported.

Given the urgency to find treatment for COVID-19, drug repurposing is the most
promising approach to identified inhibitors of SARS-CoV-2. Inhibiting the critical viral
entry pathways into host cells is a promising therapeutic possibility to combat SARSCoV-2 infection. An ideal therapeutic intervention to combat SARS-CoV-2 infection
might inhibit the viral RBD attachment to its receptor ACE2 without blocking the
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catalytic activity of ACE2, thereby preventing viral spread and dissemination into the
host system. Therefore, compounds such as OJT010 with potent efficacy, excellent
safety, and pharmacologic profile represent a promising pharmacophore candidate for
drug repurposing as possible prophylactic or treatment options against COVID-19
infection. If proven effective, this will allow rapid and cost-effective intervention to
combat SARS-CoV-2 worldwide.
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